Combination therapy
Combining anti-CD19 ADCs with anti-BCL-2 agents like venetoclax addresses systemic toxicity and resistance in CD19+ cancers, enhancing treatment efficacy and response rates.
Patent Information
- Application Number
- JP2021509758
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-10
- Filing Date
- 2019-08-30
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-08-30
AI Technical Summary
Existing antibody-drug conjugate (ADC) therapies for cancer treatment face challenges with systemic toxicity and limited efficacy, particularly in treating CD19-expressing cancers.
Combining anti-CD19 ADCs with anti-BCL-2 agents, such as venetoclax, to enhance therapeutic efficacy and overcome resistance in CD19+ cancers.
The combination therapy demonstrates synergistic effects, improving treatment outcomes for a wider range of cancers, including resistant or refractory cases, with enhanced response rates and prolonged remission durations.
Smart Images

Figure 0007590083000033 
Figure 0007590083000001 
Figure 0007590083000002
Abstract
Description
[Technical field]
[0001] Related Applications This application claims priority to UK Patent Application No. 1814207.5 filed on August 31, 2018 and UK Patent Application No. 1908225.4 filed on June 10, 2019. Technical Field The present disclosure relates to combination therapies for the treatment of pathological conditions such as cancer. In particular, the present disclosure relates to combination therapies including treatment with anti-CD19 antibody drug conjugates (anti-CD19 ADCs) and anti-BCL-2 agents. [Background technology]
[0002] [Antibody treatment] Antibody therapy has been established as a targeted treatment for subjects with cancer, immunological and angiogenic diseases (Non-Patent Document 1). Antibody-drug conjugates (ADCs), i.e., immunoconjugates, are used to target the delivery of drug moieties to tumors and intracellular deposits for the local delivery of cytotoxic or cytostatic agents, i.e., drugs that kill or inhibit tumor cells in the treatment of cancer, however, systemic administration of such unconjugated drug agents can result in unacceptable levels of toxicity in normal cells (Non-Patent Documents 2-10).
[0003] [CD19] CD19 is a 95 kDa membrane receptor that is expressed early in B cell differentiation and remains expressed until the B cell is triggered to terminally differentiate (Non-Patent Documents 11 and 12). The CD19 extracellular domain contains two C2-type immunoglobulin (jG)-like domains separated by a smaller potential disulfide-bonded domain. The CD19 cytoplasmic domain is structurally unique but highly conserved among humans, mice, and guinea pigs (Non-Patent Document 13). CD19 is part of a protein complex found on the cell surface of B lymphocytes. The protein complex includes CD19, CD21 (complement receptor, type 2), CD81 (TAPA-1), and CD225 (Leu-13) (Non-Patent Document 13).
[0004] CD19 is a key regulator of transmembrane signaling in B cells. Increases or decreases in cell surface density of CD19 affect B cell development and function, leading to diseases such as autoimmunity and hypogammaglobulinemia. The CD19 complex enhances the B cell response to antigens in vivo by cross-linking two distinct signaling complexes present on the B cell membrane. The two signaling complexes bound to membrane IgM and CD19 activate phospholipase C (PLC) by different mechanisms. Cross-linking of CD19 with the B cell receptor reduces the number of IgM molecules required for PLC activation. CD19 also functions as an adaptor protein specialized for the amplification of Arc family kinases (Non-Patent Document 14).
[0005] CD19 binding has been shown to activate or inhibit B cell activation and proliferation, depending on the amount of cross-linking that occurs (Non-Patent Document 12). CD19 is expressed in more than 90% of B cell lymphomas and is predicted to affect lymphoma proliferation in vitro and in vivo.
[0006] Therapeutic Uses of Anti-CD19 ADCs The efficacy of antibody-drug conjugates (anti-CD19-ADCs) consisting of anti-CD19 antibodies, for example in the treatment of cancer, has been established - see, for example, US Pat. Nos. 5,399,633 and 5,433,341.
[0007] Research continues to improve the efficacy, tolerability, and clinical utility of anti-CD19 ADCs, and to this end, the inventors have identified clinically advantageous combination therapies in which anti-CD19 ADCs are administered in combination with at least one anti-BCL-2 agent. [Prior art documents] [Patent documents]
[0008] [Patent Document 1] International Publication No. 2014 / 057117 [Patent Document 2] International Publication No. 2016 / 166298
Non-licensed literature
[0009] [Non-licensed document 1] Carter,P.(2006)Nature Reviews Immunology 6:343-357 [Non-licensed document 2] Xie et al(2006)Expert.Opin.Biol.Ther.6(3):281-291; [Non-licensed document 3] Kovtun et al(2006)Cancer Res.66(6):3214-3121;
Non-licensed Document 4
Non-licensed Document 5
Non-licensed Document 6
Non-licensed Document 7
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Non-licensed Document 12
[0010] The present inventors have found that the combined administration of an anti-CD19 ADC and an anti-BCL-2 agent to an individual provides unexpected clinical benefits. The present inventors have further found that administration of an anti-CD19 ADC and an anti-BCL-2 agent to an individual who has been treated or is undergoing treatment with an anti-CD19 ADC synergistically enhances the therapeutic effect. [Means for solving the problem]
[0011] Thus, in a first aspect, the disclosure provides a method of selecting an individual suitable for treatment with an anti-CD19 ADC, where the individual is selected for treatment with an anti-CD19 ADC if the individual has been or is undergoing treatment with an anti-BCL-2 agent. The individual may be selected for treatment if they are refractory to treatment or further treatment with the anti-BCL-2 agent.
[0012] In another aspect, the disclosure provides a method of treating a condition in an individual, the method comprising the steps of selecting an individual suitable for treatment by the method of the first aspect, and then administering to the individual an effective amount of an anti-CD19 ADC, the method of treatment further comprising administering the anti-CD19 ADC in combination with an anti-BCL-2 agent.
[0013] In another aspect, the disclosure provides a method of treating a condition in an individual, the method comprising administering to the individual an effective amount of an anti-CD19 ADC and an anti-BCL-2 agent. The individual may be selected for treatment by a method according to the first aspect.
[0014] The condition may be a proliferative disease, e.g., non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and leukemias, such as hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and acute lymphoblastic leukemia (ALL), such as Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL).
[0015] The anti-CD19 ADC agent can be ADCX19, as described herein.
[0016] The anti-BCL-2 agent may be venetoclax (ABT-1999), navitoclax (ABT-263), ABT-737, S55746 / BCL201, and oblimersen (G3139). Preferably, the anti-BCL-2 agent is venetoclax (ABT-1999).
[0017] The individual may be a human. The individual may be afflicted with, or may have been determined to be afflicted with, cancer. The individual may be afflicted with, or may have been determined to be, CD19+ cancer or CD19+ tumor-associated non-tumor cells (such as CD19+ infiltrating B cells).
[0018] In the disclosed methods, the anti-CD19 ADC may be administered prior to, concurrently with, or after the anti-BCL-2 agent. The disclosed methods may further include administering a chemotherapeutic agent to the individual.
[0019] In other aspects, the disclosure provides anti-CD19 ADCs, or compositions comprising anti-CD19 ADCs, for use in the therapeutic methods described herein.
[0020] In one aspect, the disclosure provides an anti-BCL-2 agent, or a composition comprising an anti-BCL-2 agent, for use in the therapeutic methods described herein.
[0021] In a further aspect, the disclosure provides for the use of an anti-CD19 ADC or an anti-BCL-2 ADC in the manufacture of a medicament for treating a condition in an individual, wherein said treatment comprises a method of treatment described herein.
[0022] In other aspects, the disclosure provides a first composition comprising an anti-CD19 ADC for use in a method of treating a condition in an individual, wherein the treatment comprises administering the first composition in combination with a second composition comprising an anti-BCL-2 agent.
[0023] In other aspects, the disclosure provides a first composition comprising an anti-CD19 ADC for use in a method of treating a condition in an individual, wherein the treatment comprises administering the first composition in combination with a second composition comprising an anti-BCL-2 agent.
[0024] The aspects also provide a first composition comprising an anti-BCL-2 agent for use in a method of treating a disease in an individual, wherein the treatment comprises administering the first composition in combination with a second composition comprising an anti-CD19 ADC.
[0025] The condition may be a proliferative disease, e.g., non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and leukemias, such as hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and acute lymphoblastic leukemia (ALL), such as Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL). The anti-CD19 ADC agent can be ADCX19, as described herein. The anti-BCL-2 agent may be venetoclax (ABT-1999), navitoclax (ABT-263), ABT-737, S55746 / BCL201, and oblimersen (G3139). Preferably, the anti-BCL-2 agent is venetoclax (ABT-1999).
[0026] The individual may be a human. The individual may be suffering from, or may have been determined to be suffering from, cancer. The individual may be suffering from, or may have been determined to be, CD19+ cancer or CD19+ tumor-associated non-tumor cells (such as CD19+ infiltrating B cells).
[0027] The first composition may be administered prior to, simultaneously with, or after administration of the second composition. The treatment may include administering to the individual a further chemotherapeutic agent.
[0028] In a further aspect, the disclosure provides for the use of an anti-CD19-ADC in the manufacture of a medicament for treating a disease in an individual, wherein the medicament comprises an anti-CD19-ADC and the treatment comprises administering an anti-BCL-2 agent in combination with a composition comprising the anti-BCL-2 agent.
[0029] The aspects also provide for the use of an anti-BCL-2 agent in the manufacture of a medicament for treating a disease in an individual, wherein the medicament comprises an anti-BCL-2 agent, and the treating comprises administering the medicament in combination with a composition comprising an anti-CD19-ADC.
[0030] The condition may be a proliferative disease, e.g., non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and leukemias, such as hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and acute lymphoblastic leukemia (ALL), such as Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL).
[0031] The anti-CD19 ADC may be ADCX19 as described herein. The anti-BCL-2 agent may be venetoclax (ABT-1999), navitoclax (ABT-263), ABT-737, S55746 / BCL201, and oblimersen (G3139). Preferably, the anti-BCL-2 agent is venetoclax (ABT-1999).
[0032] The individual may be a human. The individual may be suffering from, or may have been determined to be suffering from, cancer. The individual may be suffering from, or may have been determined to be, CD19+ cancer or CD19+ tumor-associated non-tumor cells (such as CD19+ infiltrating B cells).
[0033] The medicament may be administered prior to, simultaneously with, or after administration of the composition. The treatment may include administering to the individual a further chemotherapeutic agent.
[0034] Other aspects of the present disclosure include the following: First agent includes anti-CD19 ADC; and a package insert containing instructions for administering said first agent according to a method of treatment as disclosed herein. The kit may further include a second agent, which comprises an anti-BCL-2 agent.
[0035] In another aspect of the present disclosure, First agent includes anti-CD19 ADC; a second agent comprising an anti-BCL-2 agent; and optionally, and a package insert containing instructions for administering the first agent in combination with a second agent to an individual for the treatment of a condition.
[0036] This embodiment also provides a kit comprising an agent comprising an anti-CD19 ADC and a package insert comprising instructions for administering the agent in combination with a composition comprising an anti-BCL-2 agent to an individual for treatment of a condition. This embodiment further provides a kit comprising a pharmaceutical agent comprising an anti-BCL-2 agent and a package insert comprising instructions for administering the pharmaceutical agent in combination with a composition comprising an anti-CD19 ADC to an individual for the treatment of a Condition.
[0037] The condition may be a proliferative disease, e.g., non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and leukemias, such as hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and acute lymphoblastic leukemia (ALL), such as Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL).
[0038] The anti-CD19-ADC may be ADCX19 as described herein. The anti-BCL-2 agent may be venetoclax (ABT-1999), navitoclax (ABT-263), ABT-737, S55746 / BCL201, and oblimersen (G3139). Preferably, the anti-BCL-2 agent is venetoclax (ABT-1999).
[0039] The individual may be a human. The individual may be afflicted with cancer or may have been determined to be afflicted with cancer. The individual may have, or may have been determined to have, a CD19+ cancer or CD19+ tumor associated non-tumor cells (such as CD19+ infiltrating B cells). The agent or composition comprising the anti-CD19-ADC may be administered prior to, simultaneously with, or after the agent or composition comprising the anti-BCL-2 agent. The treatment may include administering to the individual an additional chemotherapeutic agent.
[0040] In yet a further aspect, the disclosure provides a composition comprising an anti-CD19-ADC and an anti-BCL-2 agent. This aspect of the disclosure further provides a method of treating a condition in an individual, the method comprising administering to the individual an effective amount of a composition comprising an anti-CD19-ADC and an anti-BCL-2 agent.This aspect of the disclosure further provides a composition comprising an anti-CD19-ADC and an anti-BCL-2 agent for use in the method of treating a condition in an individual.
[0041] This aspect of the disclosure further provides for the use of a composition comprising an anti-CD19-ADC and an anti-BCL-2 agent in the manufacture of a medicament for treating a condition in an individual.This aspect of the disclosure further provides for a kit comprising a composition comprising an anti-CD19-ADC and an anti-BCL-2 agent and a set of instructions for administering the medicament to an individual for treating a condition.
[0042] The condition may be a proliferative disease, e.g., non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and leukemias, such as hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and acute lymphoblastic leukemia (ALL), such as Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL). The anti-CD19 ADC agent can be ADCX19, as described herein.
[0043] The anti-BCL-2 agent may be venetoclax (ABT-1999), navitoclax (ABT-263), ABT-737, S55746 / BCL201, and oblimersen (G3139). Preferably, the anti-BCL-2 agent is venetoclax (ABT-1999).
[0044] The individual may be a human. The individual may be suffering from or have been determined to be suffering from cancer. The individual may be suffering from or have been determined to be suffering from CD19+ cancer or CD19+ tumor associated non-tumor cells (such as CD19+ infiltrating B cells). The treatment may include administering a further chemotherapeutic agent to the individual. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0045] [Antibody drug conjugates (ADCs)] ADCs can deliver drugs to target sites. The target site is preferably a proliferative cell population. The antibody is directed against an antigen present on the proliferative cell population. In one embodiment, the antigen is absent in a non-proliferative cell population or is present at a reduced level compared to the amount of antigen present in the proliferative cell population, e.g., a tumor cell population. The ADC may include a linker that may be cleaved to release the drug at the target site. The drug may be a compound selected from RelA, RelB, RelC, RelD, or RelE. That is, the conjugate may be used to selectively deliver the compound RelA, RelB, RelC, RelD, or RelE to a target site. The linker may be cleaved by an enzyme present at the target site. The present disclosure specifically relates to treatment with the anti-CD19 ADCs disclosed in US Pat. No. 6,399,433 and herein.
[0046] [Anti-CD19 ADCs] As used herein, the term "anti-CD19 ADC" or "CD19-ADC" refers to an ADC in which the antibody component is an anti-CD19 antibody. The term "PBD-ADC" refers to an ADC in which the drug moiety is a pyrrolobenzodiazepine (PBD) warhead. The term "anti-CD19 ADC" refers to an ADC in which the antibody moiety is an anti-CD19 ADC antibody and the drug moiety is a PBD warhead. The ADC has the formula L-(D L )p complex, where D L is represented by the following formula I or II:
[0047] [ka] (In the formula, L is an antibody (Ab) that is an antibody that binds to CD19; If there is a double bond between C2' and C3', R 12 below: (ia) optionally halo, nitro, cyano, ether, carboxy, ester, C 1~7 Alkyl, C 3~7 Heterocyclyl and bis-oxy-C 1~3 substituted by one or more substituents selected from the group consisting of alkylene, 5~10 Aryl groups; (ib)C 1~5 Saturated fatty alkyl; (ic)C 3~6 Saturated cycloalkyl; (id)
[0048] [ka] (In the formula, R 21 , R 22 and R 23 are each independently H, C 1~3 Saturated alkyl, C 2~3 Alkenyl, C 2~3 alkynyl and cyclopropyl; R 12 the total number of carbon atoms in the group is 5 or less); (ie)
[0049] [ka] (In the formula, R 25a and R 25b one of which is H and the other is selected from halo, methyl, methoxy; phenyl optionally substituted with a group selected from pyridyl; and thiophenyl; (if)
[0050] [ka] (In the formula, R 24 is H;C 1~3 Saturated alkyl;C 2~3 Alkenyl; C 2~3 alkynyl; cyclopropyl; phenyl optionally substituted with a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; selected from the group consisting of; If there is a single bond between C2' and C3', R 12 below:
[0051] [ka] (In the formula, R 26a and R 26b are independently H, F, C 1~4 Saturated alkyl, C 2~3 alkenyl, the alkyl and alkenyl groups being optionally selected from 1~4 Alkylamide and C 1~4 or R 26a and R 26b When one of the groups is H, the other is a nitrile and C 1~4 alkyl esters; R 6 and R 9is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn, and halo; where R and R′ are independently optionally substituted C 1~12 Alkyl, C 3~20 Heterocyclyl and C 5~20 aryl groups; R 7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn, and halo; R” is C 3~12 It is an alkylene group, the chain of which may contain one or more heteroatoms, such as O, S, NR N2 (where R N2 is H or C 1~4 alkyl), and / or may be interrupted by aromatic rings, such as benzene or pyridine; Y and Y' are selected from O, S or NH; R 6’ , R 7’ and R 9’ are R 6 , R 7 and R 9 and selected from the same groups as above; [Formula I] R L1’ is a linker that binds to the antibody (Ab); R 11a OH, OR A And R A is C 1~4 alkyl, and SOzM, where z is 2 or 3 and M is a monovalent pharma- ceutically acceptable cation; R 20 and R 21 both form a double bond between the nitrogen atom and the carbon atom to which they are attached, or; R 20 H and R C is selected from, where R C is a capping group; R 21 OH, OR A and SOzM; If there is a double bond between C2 and C3, R 2 below: (ia) optionally halo, nitro, cyano, ether, carboxy, ester, C 1~7 Alkyl, C 3~7 Heterocyclyl and bis-oxy-C 1~3 C substituted by one or more substituents selected from the group consisting of alkylene 5~10 Aryl groups; (ib)C 1~5 Saturated fatty alkyl; (ic)C 3~6 Saturated cycloalkyl; (id)
[0052] [ka] (In the formula, R 11 , R 12 and R 13 are each independently H, C 1~3 Saturated alkyl, C 2~3 Alkenyl, C 2~3 alkynyl and cyclopropyl, where R 2 the total number of carbon atoms in the group is 5 or less; (ie)
[0053] [ka] (In the formula, R 15a and R 15b one of which is H and the other is selected from phenyl and thiophenyl, optionally substituted with a group selected from halo, methyl, methoxy; pyridyl; (if)
[0054] [ka] (In the formula, R 14 is H;C 1~3 Saturated alkyl;C 2~3 Alkenyl; C 2~3alkynyl; cyclopropyl; phenyl optionally substituted with a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl); selected from the group consisting of; If there is a single bond between C2 and C3, R 2 teeth,
[0055] [ka] (In the formula, R 16a and R 16b are independently H, F, C 1~4 Saturated alkyl, C 2~3 alkenyl, the alkyl and alkenyl groups being optionally selected from 1~4 Alkylamide and C 1~4 or R 16a and R 16b When one of the groups is H, the other is a nitrile and C 1~4 selected from alkyl esters); [Formula II] R 22 is of formula IIIa, IIIb or IIIc: (a)
[0056] [ka] (Wherein, A is C 5~7 An aryl group, such as: (i)Q 1 is a single bond and Q 2 is a single bond and -Z-(CH2) n -, where Z is selected from a single bond, O, S and NH, and n is 1 to 3; or (ii)Q 1 is -CH=CH- and Q2 is a single bond; (b)
[0057] [ka] (In the formula, R C1 , R C2 and R C3 are independently H and unsubstituted C 1~2 selected from alkyl; (c)
[0058] [ka] (wherein Q is OR L2’ , S.R. L2’ and N.R. N -R L2’ Selected from R N is selected from H, methyl and ethyl; X is OR L2’ , S.R. L2’ , CO2-R L2’ , C.O.R. L2’ , NH-C(=O)-R L2’ , NHNH-R L2’ , CONHNH-R L2’ ,
[0059] [ka] , N.R. N R L2’ wherein R N H and C 1~4 selected from the group including alkyl; R L2’ is a linker that binds to an antibody (Ab); R 10 and R 11 both form a double bond between the nitrogen atom and the carbon atom to which they are attached, or R 10 is H and R 11 OH, OR A and SOzM; R 30 and R 31 both form a double bond between the nitrogen atom and the carbon atom to which they are attached, or R30 is H and R 31 OH, OR A and SOzM).
[0060] In one embodiment, the LR L1’ or L.R. L2’ is the following group:
[0061] [ka] where the asterisk indicates the point of attachment to the PBD, Ab is the antibody, and L 1 is a cleavable linker, and A is L 1 is a linking group that links 2 is a covalent bond or, together with -OC(=O)-, forms a self-impermeable linker). In some of such embodiments, L 1 can be cleaved enzymatically. Such ADCs have previously been shown to be useful in treating CD19-expressing cancers (see, for example, US Patent Publication 2005 / 0133962, the entirety of which is incorporated herein by reference).
[0062] The term "anti-CD19-ADC" includes any of the embodiments described in WO 2007 / 023991. In particular, in preferred embodiments, the ADC comprises one of the following:
[0063] [ka] (wherein the Ab is a CD19 antibody and the DAR is 1 to 8). There may be a chemical structure.
[0064] The antibody comprises a VH domain having the sequence of any one of SEQ ID NOs: 1, 2, 3, 4, 5, or 6, and optionally further comprises a VL domain having the sequence of any one of SEQ ID NOs: 7, 8, 9, 10, 11, or 12.
[0065] In certain aspects, the antibody component of the anti-CD19-ADC is an antibody that comprises a VH domain and a VL domain having the sequences of SEQ ID NO:1 and SEQ ID NO:7, SEQ ID NO:2 and SEQ ID NO:8, SEQ ID NO:3 and SEQ ID NO:9, SEQ ID NO:4 and SEQ ID NO:10, SEQ ID NO:5 and SEQ ID NO:11, or SEQ ID NO:6 and SEQ ID NO:12, respectively.
[0066] In a preferred embodiment, the antibody comprises a VH domain having the sequence of SEQ ID NO: 2. In a preferred embodiment, the antibody comprises a VL domain having the sequence of SEQ ID NO: 8.
[0067] In a preferred embodiment, the antibody comprises a VH domain having the sequence of SEQ ID NO:2 and a VL domain having the sequence of SEQ ID NO:8.
[0068] The VH and VL domains are capable of pairing to form an antibody antigen-binding site that binds to CD19.
[0069] In one embodiment, the antibody is an intact antibody comprising a VH domain and a VL domain, wherein the VH domain and the VL domain have the sequences of SEQ ID NO:2 and SEQ ID NO:8.
[0070] In one embodiment, the antibody comprises a long chain having the sequence of SEQ ID NO:13 and a light chain having the sequence of SEQ ID NO:14.
[0071] In one embodiment, the antibody is a fully human monoclonal IgG1 antibody, preferably an IgG1 ,κ It is.
[0072] In one embodiment, the antibody is the RB4v1.2 antibody described in US Pat. No. 5,399,633.
[0073] In one aspect, the antibody is an antibody described herein with the modifications (or further modifications) described below. In one embodiment, the antibody is a humanized, deimmunized or resurfaced antibody of the antibodies disclosed herein.
[0074] A preferred anti-CD19 ADC for use with this embodiment of the disclosure is ADCx19, described below. A second preferred anti-CD19 ADC for use with this embodiment of the disclosure is ADCT-301.
[0075] ADCx19 ADCx19 is an antibody-drug conjugate composed of a humanized antibody against human CD19 linked to a pyrrolobenzodiazepine (PBD) warhead via a cleavable linker. The mechanism of action of ADCX19 relies on CD19 binding. CD19-specific antibodies target the antibody-drug conjugate (ADC) to cells expressing CD19. Upon binding, the ADC is internalized and transported to lysosomes, where the protease-sensitive linker is cleaved and the free PBD dimer is released into the target cell. The released PBD dimer inhibits transcription in a sequence-selective manner due to direct inhibition of RNA polymerase or inhibition of the interaction of relevant transcription factors. The PBD dimer creates covalent crosslinks that are not recognized by nucleotide excision repair factors without distorting the DNA double helix, which may result in a longer effective period (Hartley 2011).
[0076] This includes:
[0077] [ka] It has a chemical structure.
[0078] Ab represents the antibody RB4v1.2 (fully human monoclonal IgG1, K antibody with VH and VL sequences SEQ ID NOs: 2 and 8, respectively). It was synthesized as described in WO 2006 / 023391 (RB4v1.2-E) and typically has a DAR (drug to antibody ratio) of 2.0+ / -0.3.
[0079] [ CD19 binding 〕 As used herein, "binds to CD19" means that the antibody binds to CD19 with higher affinity than a nonspecific partner such as bovine serum albumin (BSA, Genbank Accession No. CAA76847 version number CAA76847.1 GI:3336842 record updated on January 7, 2011 at 2:30 PM). In certain embodiments, ... the association constant of the antibody for BSA when measured under physiological conditions, such as at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 1000, 2000, 5000, 1000, 2000, 3000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 100 4 , 10 5 or 10 6 The antibodies of the invention may bind to CD19 with high affinity. For example, in some embodiments, the antibodies bind to CD19 with an association constant (Ka) that is 1×10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 , 10 -13 or 10 -14 Less than 1, about 10 -6 K is equal to or less than M D It can bind to CD19.
[0080] In one embodiment, the CD19 polypeptide corresponds to Genbank Accession No. NP_001171569 Version No. NP_001171569.1 GI:296010921; record updated on Sep. 10, 2012 at 12:43 AM. In one embodiment, the nucleic acid encoding the CD19 polypeptide corresponds to Genbank Accession No. NM_001178098, Version No. NM_001178098.1 Gi:296010920; Recorded on September 10, 2012 at 12:43 AM. In an embodiment, the CD19 polypeptide corresponds to Uniprot / Swiss-Prot Accession No. P15391.
[0081] [Anti-BCL-2 agents] Suitable anti-BCL-2 agents include venetoclax (ABT-1999), navitoclax (ABT-263), ABT-737, S55746 / BCL201, and oblimersen (G3139). Preferably, the anti-BCL-2 agent is venetoclax (ABT-1999).
[0082] BCL-2 localizes to the outer mitochondrial membrane and plays an important role in promoting cell survival and inhibiting the action of pro-apoptotic proteins. The pro-apoptotic proteins in the BCL-2 family, including Bax and Bak, usually act on the mitochondrial membrane to promote the permeabilization and release of cytochrome C and ROS, key signals in the apoptotic cascade. The pro-apoptotic proteins are in turn activated by BH3-only proteins and inhibited by the function of BCL-2 and associated BCL-XI. The dynamic functions of pro- and anti-apoptotic proteins, among others, may account for the significant difference in the upregulation of BCL-2 expression in human diseases. However, a wide variety of cancer types are associated with aberrant expression of BCL-2 (both hematological and non-hematological solid tumors), consistent with a function of BCL-2 as a regulator of apoptosis (Hanada M. et al., Blood. 1993;82:1820-1828; Campos L. et al., Blood. 1993;81:3091-3096; Lamers F. et al., Eur J Cancer. 2012;48:3093-3103). As used herein, an "anti-BCL-2 agent" refers to any agent that specifically binds to BCL-2 and / or inhibits the biological activity of BCL-2. As used herein, "binds to BCL-2" means that the antibody binds to BCL-2 with higher affinity than a non-specific partner such as bovine serum albumin (BSA, Genbank Accession No. CAA76847 Version No. CAA76847.1 GI:3336842; last recorded on Jan. 7, 2011 at 2:30 p.m.). In certain embodiments, the antibody binds to BCL-2 with an affinity at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 50 ... 4 , 10 5 or 10 6 The agent may bind to BCL-2 with high affinity. For example, in some embodiments, the antibody binds to BCL-2 with an association constant (Ka) that is 1×10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 , 10 -13 or 10 -14 Less than 1, about 10 -6 K is equal to or less than M D It can bind to BCL-2.
[0083] In one aspect, the BCL-2 polypeptide corresponds to Genbank Accession No. AAB72092, Version No. AAB72092.1 Record Last Updated: July 24, 2016 at 2:22 PM. In one embodiment, the nucleic acid encoding the BCL-2 polypeptide corresponds to Genbank Accession No. AF021792 Record Last Updated: July 24, 2016 at 2:22 PM. In one aspect, the BCL-2 polypeptide corresponds to Uniprot / Swiss-Prot Accession No. Q92934.
[0084] To demonstrate that anti-CD19 ADCs function synergistically with anti-BCL-2 agents, a panel of CD19(+) cell lines is co-treated with varying concentrations of anti-CD19 ADCs and anti-BCL-2 agents, respectively. As a negative control, the same panel of cell lines is treated with varying concentrations of anti-BCL-2 agents or varying concentrations of anti-CD19 ADCs and vehicle. After incubation, two parameters are measured: surface CD19 (determined by flow cytometry) and the in vitro cytotoxicity of the combination (determined by MTS assay). To determine cytotoxicity, MTS is added to each well and incubated at 37°C for 4 hours to measure cell viability. Cell viability is calculated relative to untreated control. Cytotoxicity synergy is calculated by transferring cell viability data to affected fractions and calculating its combination index using CalcuSyn fraction analysis program.
[0085] Anti-CBCL-2 agents suitable for use in the present disclosure include: a) Venetoclax
[0086] [ka] b) Navitoclax (ABT-263)
[0087] [ka] c) ABT-737
[0088] [ka] d) S55746 / BCL201
[0089] [ka] e) Oblimersen (G3139)
[0090] [ka] Advantageous Properties of the Combinations of the Present Disclosure Both anti-CD19 ADCs and anti-BCL-2 agents have demonstrated clinical utility when used alone as single agents, e.g., in the treatment of cancer. However, as described herein, the combination of an anti-CD19 ADC and an anti-BCL-2 agent provides the following benefits over treatment with either an anti-CD19 ADC or an anti-BCL-2 agent alone: 1) It is effective in treating a wider range of cancers; 2) Effective treatment of individuals suffering from resistant or refractory conditions, such as cancer, that have relapsed after a period of remission; 3) Improving response rates to treatment; and / or 4) improved persistence of treatment; It is expected that one or more of the following advantages will be achieved:
[0091] As used herein, effective treatment of a broader range of cancers means that complete responses are observed in a broader range of recognized cancer types following the combination treatment, i.e., complete responses are observed in cancer types that were previously reported to be incompletely responsive to either the anti-CD19 ADC or the anti-BCL-2 agent alone.
[0092] As used herein, effective treatment of a resistant, refractory, or recurrent condition means that after treatment with the combination, a complete response is observed in individuals who are partially or completely resistant or refractory to treatment with an anti-CD19 ADC or an anti-BCL-2 agent alone (e.g., individuals who have no response or only a partial response after anti-CD19 ADC or anti-BCL-2 agent monotherapy, or individuals whose condition has relapsed). In some embodiments, a complete response after anti-CD19 ADC / anti-BCL-2 agent combination treatment is observed in at least 10% of individuals who are partially or completely resistant or refractory to treatment with an anti-CD19 ADC or anti-BCL-2 agent alone. In some embodiments, a complete response following anti-CD19 ADC / anti-BCL-2 agent combination treatment is observed in at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% of individuals who are partially or completely resistant or refractory to anti-CD19 ADC or anti-BCL-2 agent monotherapy.
[0093] As used herein, improved response rate to treatment means that a higher percentage of individuals experience a complete response following combination treatment than is observed following monotherapy with either the anti-CD19 ADC or the anti-BCL-2 agent. In some embodiments, a complete response following combination treatment with the anti-CD19 ADC / anti-BCL-2 agent is observed in at least 10% of treated individuals. In some embodiments, a complete response following combination treatment with the anti-CD19 ADC / anti-BCL-2 agent is observed in at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% of treated individuals.
[0094] Improved durability of treatment as used herein means that the mean duration of complete response in combination treated individuals is longer than individuals who achieve a complete response following monotherapy with either the anti-CD19 ADC or the anti-BCL-2 agent. In some embodiments, the mean duration of complete response following combination therapy with the anti-CD19 ADC / anti-BCL-2 agent is at least 6 months. In some embodiments, the mean duration of complete response following combination therapy with the anti-CD19 ADC / anti-BCL-2 agent is at least 12 months, at least 18 months, at least 24 months, at least 3 years, at least 4 years, at least 5 years, at least 6 years, at least 7 years, at least 8 years, at least 9 years, at least 10 years, at least 15 years, or at least 20 years.
[0095] As used herein, "complete response" means no clinical evidence of disease in an individual. Evidence can be assessed using any suitable method in the art, such as CT or PET scan, or biopsy, if appropriate. The number of doses required to achieve a complete response may be 1, 2, 3, 4, 5, 10 or more. In some embodiments, an individual achieves a complete response within 1 year of administration from the initial dose, such as within 6 months, 3 months, 1 month, 2 weeks, or 1 week after administration of the first dose.
[0096] [Symptoms to be treated] Combination therapies described herein include those that have utility in anti-cancer activity. In particular, in certain embodiments, the therapy includes an antibody that is covalently linked, i.e., via a linker, to a PBD drug moiety, i.e., a toxin. When the drug is not bound to the antibody, the PBD drug has a cytotoxic effect. The biological activity of the PBD drug moiety is modulated, i.e., upon binding to the antibody. The antibody drug conjugates (ADCs) of the present disclosure achieve selective delivery of an effective amount of a cytopathic drug to tumor tissue with higher selectivity, i.e., lower effective doses.
[0097] Thus, in certain aspects, the disclosure provides combination therapies comprising administration of an anti-CD19 ADC that binds CD19 for use in therapy, where the method comprises selecting a subject based on expression of a target protein.
[0098] Thus, in certain aspects, the disclosure provides combination therapies comprising administration of an anti-CD19 ADC that binds CD19 for use in therapy, where the method comprises selecting a subject based on expression of a target protein.
[0099] In one aspect, the disclosure provides a combination therapy comprising a label that identifies the therapy as suitable for use in a subject determined to be suitable for use. The label may identify the therapy as suitable for use in a subject that expresses CD19, such as overexpressing CD19. The label may identify the subject as having a particular cancer type.
[0100] The cancer may be a lymphoma, such as non-Hodgkin's lymphoma. The label may identify the subject as having CD19+ lymphoma. In a further aspect, there is also provided a combination therapy as described herein for use in treating a proliferative disease. In another aspect of the present disclosure, there is provided the use of a conjugate in the manufacture of a medicament for the treatment of a proliferative disease.
[0101] One of ordinary skill in the art can readily determine whether a candidate combination therapy treats a proliferative disorder of any particular cell type. For example, described below are assays that can be conveniently used to evaluate the activity offered by a particular compound.
[0102] The combination therapies described herein can be used to treat proliferative disorders. The term "proliferative disorder" relates to unwanted or uncontrolled, excessive or abnormal cell proliferation, e.g., neoplastic or hyperplastic proliferation, whether in vitro or in vivo.
[0103] Examples of proliferative conditions include, but are not limited to, benign, pre-malignant, and malignant cell proliferation; These include, but are not limited to, neoplasms and tumors (e.g., histocytoma, glioma, astrocytoma, osteoma), cancer (e.g., lung cancer, small cell lung cancer, gastrointestinal cancer, colorectal cancer, colon cancer, breast cancer, ovarian cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma), lymphoma, leukemia, psoriasis, bone disease, fibroproliferative conditions (e.g., connective tissue), and atherosclerosis. Associated cancers include, but are not limited to, leukemia and ovarian cancer. Any cell type may be treated, including, but not limited to, lung, gastrointestinal tract (including, e.g., large intestine, colon), breast (mammary), ovary, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin.
[0104] Particularly relevant proliferative disorders include non-Hodgkin's lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and leukemias such as hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and acute lymphoblastic leukemia (ALL), such as Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL) [Fielding A., Haematologica. 2010Jan;95(1):8-12].
[0105] It is contemplated that the combination therapies of the present disclosure may be used to treat a variety of diseases or conditions that are characterized, for example, by overexpression of tumor antigens. Exemplary conditions or hyperproliferative disorders include benign or malignant tumors, leukemias, hematological malignancies, and lymphoid malignancies. Others include neuronal, glial, astrocytic, hypothalamic, glandular, macrophagal, epithelial, interstitial, blastocytic, inflammatory, angiogenic, and immune disorders, including autoimmune disorders and graft-versus-host disease (GVHD).
[0106] Generally, the disease or condition being treated is a hyperproliferative disease, such as cancer. Examples of cancers to be treated herein include, but are not limited to, epithelial carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More specific examples of such cancers include squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer including small cell lung cancer and non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal or gastric cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, anal cancer, penile cancer, and head and neck cancer.
[0107] Autoimmune diseases for which the combination therapy may be used to treat include rheumatic diseases (such as rheumatoid arthritis, Sjogren's syndrome, scleroderma, lupus, including SLE and lupus nephritis, polymyositis / dermatomyositis, cryoglobulinemia, antiphospholipid syndrome, and psoriatic arthritis), osteoarthritis, autoimmune gastrointestinal and liver diseases (such as inflammatory bowel disease (ulcerative colitis and Crohn's disease), autoimmune gastritis and pernicious anemia, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and celiac disease), vasculitis (ANCA-associated vasculitis, including Tuerg-Strauss vasculitis, Wegener's granulomatosis, and polyarteritis), autoimmune neurological conditions (multiple sclerosis, myoclonus syndrome, myasthenia gravis, neuromyelitis optica, Parkinson's disease, Alzheimer's disease, and autoimmune autoimmune polyneuropathy, etc.), renal symptoms (glomerulonephritis, Goodpasture's syndrome, Berger's disease, etc.), autoimmune skin diseases (e.g., psoriasis, urticaria, hives, pemphigus vulgaris, bullous pemphigus, cutaneous lupus erythematosus, etc.), blood symptoms (thrombocytopenic purpura, thrombotic thrombocytopenic purpura, post-transfusion purpura, autoimmune hemolytic anemia, etc.), arteriosclerosis, uveitis, autoimmune hearing diseases (e.g., inner ear disease and hearing loss, etc.), Behcet's disease, Raynaud's syndrome, organ transplantation, graft-versus-host disease (GVHD), and autoimmune endocrine diseases (diabetes-related autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM), Addison's disease, and autoimmune thyroid diseases (e.g., Graves' disease and thyroiditis)). More preferred examples of the disease include rheumatoid arthritis, ulcerative colitis, ANCA-associated vasculitis, lupus, multiple sclerosis, Sjogren's syndrome, Graves' disease, IDDM, pernicious anemia, thyroiditis, and glomerulonephritis.
[0108] In certain aspects, the subject has a proliferative disease selected from non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and leukemias such as hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and acute lymphoblastic leukemia (ALL), such as Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL) [Fielding A., Haematologica. 2010 Jan; 95(1):8-12]. In one embodiment, the subject has diffuse large B-cell lymphoma.
[0109] [Patient Selection] In some embodiments, prior to administration of the treatments, individuals believed to be suitable for treatment with the combination treatment are selected. As used herein, an individual who is considered suitable for treatment is an individual who is expected to benefit from or respond to the treatment. The individual may have, be suspected of, or be at risk of cancer. The individual may have been diagnosed with cancer. In particular, the individual may have, be suspected of, or be at risk of lymphoma. In some cases, the individual may have, be suspected of, or be at risk of having a solid cancer with tumor-associated non-tumor cells that express CD19, such as infiltrating cells that express CD19.
[0110] In some embodiments, the individual is selected based on the amount or pattern of expression of CD19, hi certain embodiments, the selection is based on cell surface expression of CD19. In some embodiments, the target is BCL-2. In some embodiments, the selection is based on expression of BCL-2. In some embodiments, the selection is based on the levels of both CD19 and BCL-2 at the cell surface.
[0111] In some cases, expression of the assay is measured in a specific tissue of interest, for example in a sample of lymphatic or tumor tissue. In some cases, systemic expression of the target is determined, for example in a sample of a circulating fluid such as blood, plasma, serum, or lymph.
[0112] In some embodiments, the individual is selected as suitable for treatment due to the presence of target expression in the sample, in which case individuals without target expression would not be suitable for treatment. In other embodiments, the level of target expression is used to select individuals suitable for treatment: if the expression level of the target exceeds a threshold level, the individual is deemed suitable for treatment. In some embodiments, the presence of CD19 in the sample and / or CD19 in the cells indicates that the individual is suitable for a combination treatment comprising an anti-CD19 ADC and an anti-BCL-2 agent. In other embodiments, the amount of CD19 and / or expression must be above a threshold level to indicate that the individual is suitable for treatment. In some embodiments, the observation that CD19 and / or localization is altered in the sample compared to a control indicates that the individual is suitable for treatment. In some embodiments, the individual is indicated as suitable for treatment if cells obtained from the lymph node or extranodal site react with antibodies to CD19 and / or as determined by IHC.
[0113] In some embodiments, a patient is deemed suitable for treatment if at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more of the total cells in the sample express CD 19. In some embodiments disclosed herein, a patient is deemed suitable for treatment if at least 10% of the cells in the sample express CD 19. In some embodiments, a patient is determined to be suitable for treatment if at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more of the total cells in the sample express CD 19. In some embodiments disclosed herein, a patient is determined to be suitable for treatment if at least 10% of the cells in the sample express CD 19.
[0114] In some aspects, the individual is selected for treatment based on current or previous treatment regimes. In some embodiments, the individual is selected for treatment with an anti-CD19 ADC if the individual has been treated with an anti-BCL-2 agent. In some embodiments, the individual is selected for treatment with an anti-CD19 ADC if the individual is being treated with an anti-BCL-2 agent. In some cases, the individual is selected for treatment if the individual is resistant to treatment (or further treatment) with an anti-BCL-2 agent. In some cases, the anti-BCL-2 agent may be venetoclax. In embodiments where the individual is undergoing or has undergone treatment with an anti-BCL-2 agent, the anti-CD19 ADC may be administered in combination with the anti-BCL-2 agent or without continued administration of the anti-BCL-2 agent. In some embodiments, the anti-CD19 ADC is administered to the selected individual in combination with an anti-BCL-2 agent. In some embodiments, the anti-CD19 ADC may be administered to the selected individual without the ongoing administration of an anti-BCL-2 agent. The anti-BCL-2 agent may preferably be venetoclax.
[0115] As used herein, the term "refractory to treatment (or further treatment) with an anti-BCL-2 agent" means that the condition (e.g., cancer) is not responsive or has become refractory when administered alone with an anti-BCL-2 agent. In some embodiments, individuals with refractory NHL are identified using the response criteria disclosed in Cheson at al. 2014 (South Asian J Cancer. 2014 Jan-Mar; 3(1): 66-70). In that document, non-responders are defined as individuals who have either: (i) a greater than 50% increase in the sum product of the diameters of any previously identified abnormal nodules from nadir; or (ii) the appearance of any new lesions during or at the end of treatment. In some embodiments, individuals with refractory leukemia are identified as those with stable or progressive disease who have completed one complete cycle of treatment, or those who have achieved a partial response after two or more complete cycles of treatment.
[0116] As used herein, the term "undergoing treatment" means that an individual has either taken the medication within the past three weeks or is scheduled to take the medication within the next three weeks. In some embodiments, the term "treated with" as used herein means that the individual is taking a given medication in the same treatment cycle. As used herein, the term "had been treated with" means that an individual had taken the agent at some past time. In some embodiments, the term "has been treated with" as used herein means that the individual has taken a given medication within the past 12 months, e.g., within the past 3 months. In some embodiments, the term "had been treated" as used herein means that the individual had taken an agent of the invention in the immediately preceding prior treatment cycle.
[0117] sample The sample may comprise or be derived from the following: a volume of blood, a volume of serum derived from an individual's blood including the fluid portion of blood obtained after removal of fibrin clots and blood cells, a volume of pancreatic juice, a tissue sample or biopsy, or cells isolated from said individual. Samples may be taken from any tissue or body fluid. In certain aspects, the sample may be or be derived from a tissue sample, biopsy, resection, or cells isolated from said individual. In some embodiments, the sample is a tissue sample. The sample may be a sample of tumor tissue, such as a cancerous tumor tissue. The sample may be obtained by tumor biopsy. In some embodiments, the sample is a lymphatic tissue sample, such as a lymphatic lesion sample or a lymph node biopsy. In some embodiments, the sample is a skin biopsy.
[0118] In some embodiments, the sample is taken from a bodily fluid, more preferably a bodily fluid circulating within the body. That is, the sample may be a blood sample or a lymphatic fluid sample. In some embodiments, the sample is a urine sample or a saliva sample. In some embodiments, the sample is a blood sample or a blood-derived sample, which may be a selected fraction of an individual's blood, such as a selected cell-containing fraction or a plasma or serum fraction. The selected cell-containing fraction may contain relevant cell types, including white blood cells (WBCs), in particular peripheral blood mononuclear cells (PBCs) and / or granulocytes, and / or red blood cells (RBCs). That is, a method according to the present disclosure may comprise detecting a first target polypeptide or nucleic acid in blood, in white blood cells, peripheral blood mononuclear cells, granulocytes and / or red blood cells. The sample may be fresh or archived. For example, the archived tissue may be a biopsy of the individual at the time of initial diagnosis or at the time of recurrence. In certain aspects, the sample is a fresh biopsy. The first target polypeptide may be CD19.
[0119] Individual Status The individual may be an animal, a mammal, a viviparous mammal, a marsupial (e.g., kangaroo, wombat), a monocephalic (e.g., duck, platypus), a rodent (e.g., guinea pig, hamster, rat, mouse), a murine (e.g., mouse), a lagomorph (e.g., rabbit), an avian (e.g., bird), a canine (e.g., dog), a feline (e.g., cat), an equine (e.g., horse), a porcine (e.g., pig), an ovine (e.g., sheep), a bovine (e.g., cow), a primate, an ape (e.g., monkey or ape), a primate (e.g., marmoset, baboon), ape (e.g., gorilla, chimpanzee, orangutan, geese), or a human. Furthermore, the individual may be in any form of development, for example, a fetus. In a preferred embodiment, the individual is a human. As used herein, the terms "subject," "patient," and "individual" are used interchangeably.
[0120] In some embodiments disclosed herein, the individual has been identified as having, suspected of having, or at risk of having cancer. In some embodiments disclosed herein, the individual has already been diagnosed with cancer. The individual may have been diagnosed with non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and leukemia, such as hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and acute lymphoblastic leukemia (ALL), such as Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL). [Fielding A., Haematologica.2010Jan;95(1):8-12]. In some cases, the individual may have been diagnosed with a leukemia, such as non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and acute lymphoblastic leukemia (ALL), such as hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL). [Fielding A., Haematologica.2010Jan;95(1):8-12].
[0121] In some cases, the individual has been diagnosed with a solid tumor that contains infiltrating cells that express CD19+. The individual is undergoing or has undergone therapeutic treatment for the cancer. The subject may or may not have previously taken ADCX19. In some cases, the cancer is a lymphoma, including non-Hodgkin's lymphoma. The individual may be undergoing or have undergone treatment with an anti-BCL-2 agent. In some cases, the individual may be resistant to treatment (or further treatment) with an anti-BCL-2 agent. In some cases, the anti-BCL-2 agent may be venetoclax. In embodiments where the individual is undergoing or has undergone treatment with an anti-BCL-2 agent, the anti-CD19 ADC may be administered in combination with the anti-BCL-2 agent or without continued administration of the anti-BCL-2 agent.
[0122] Control In some aspects, target expression in an individual is compared to target expression in a control, which is useful for supporting the validity of staining and identifying experimental artifacts. In some cases, the control may be a reference sample or a reference data set. The reference may be a sample previously obtained from an individual with a known degree of suitability. The reference may be a data set obtained by analyzing a reference sample.
[0123] The control may be a positive control in which the target molecule is known to be present or expressed at high levels, or a negative control in which the target molecule is known to be absent or expressed at low levels. The control may be a tissue sample taken from an individual known to benefit from the treatment. The tissue may be of the same species as the sample being tested, for example a sample of tumor tissue from an individual may be compared to a control sample of tumor tissue from an individual known to be suitable for the treatment, such as an individual who has previously responded to the treatment.
[0124] In some cases, the control may be a sample obtained from the same individual as the test sample, but may be a sample obtained from tissue known to be healthy. Thus, a sample of cancerous tissue from an individual may be compared to a non-cancerous tissue sample. In some cases, the control is a cell culture sample.
[0125] In some cases, the test sample is analyzed prior to incubation with the antibody to determine the level of background staining inherent to the sample. In some cases, isotype controls are used, which use antibodies of the same class as the target-specific antibody, but which are not immunoreactive with the sample, and are useful for distinguishing non-specific interactions of the target-specific antibody.
[0126] The method may include a hematopathologist's interpretation of the morphology and immunohistochemistry to ensure accurate interpretation of the test results. The method may include a step of confirming that the expression pattern correlates with an expected pattern. For example, when analyzing the expression levels of CD19 and / or BCL-2, the method may include a step of confirming that expression is observed in the test sample as a membrane staining with cytoplasmic components. The method may include a step of confirming that the ratio of target signal to noise is above a threshold level, so that specific and non-specific background signals can be clearly distinguished.
[0127] [Treatment method] The term "treatment" as used herein in the context of treating a condition generally relates to treatment and therapy, whether in humans or animals (e.g., in veterinary applications), where some desired therapeutic effect is achieved, e.g., inhibition of progression of the condition, slowing the rate of progression, halting the rate of progression, regressing the condition, ameliorating the condition, and curing the condition. Treatment as a preventative measure (i.e., prophylaxis, prevention) is also included.
[0128] As used herein, the term "therapeutically effective amount" or "effective amount" means an amount of an active compound, or a material, composition, or dosage containing an active compound, that is effective to produce some desired therapeutic effect, commensurate with a reasonable benefit / risk ratio, when administered in accordance with a desired treatment regimen. Similarly, the term "prophylactically effective amount" as used herein means an amount of active compound, or material, composition or dosage containing an active compound, that is effective to produce a desired prophylactic effect, commensurate with a reasonable benefit / risk ratio, when administered in accordance with a desired treatment regimen.
[0129] The present specification discloses a method of treatment. Also provided is a method of treatment comprising administering to a subject in need of treatment a therapeutically effective amount of an anti-CD19 ADC and an anti-BCL-2 agent. The term "therapeutically effective amount" is an amount sufficient to provide a benefit to the subject. The benefit may be at least an improvement in at least one symptom. The actual amount administered, and the rate and time course of administration, will depend on the nature and severity of the individual being treated. Prescribing treatment, e.g., determining the dosage, is within the responsibility of the medical practitioner or other physician. The subject may be tested to determine eligibility to be treated by the methods disclosed herein. The method of treatment may include determining whether the subject is eligible to be treated by the methods disclosed herein.
[0130] The anti-CD19 ADC comprises an anti-CD19 antibody. The anti-CD19 antibody may be an RB4v1.2 antibody. The ADC may comprise a drug that is a PBD dimer. The ADC may be ADCx19. The ADC may be an ADC disclosed in US Pat. No. 6,399,636. The anti-BCL-2 agent may be venetoclax (ABT-1999), navitoclax (ABT-263), ABT-737, S55746 / BCL201, and oblimersen (G3139). Preferably, the anti-BCL-2 agent is venetoclax (ABT-1999).
[0131] Such treatments include the administration of an anti-CD19 ADC / anti-BCL-2 agent combination alone or in further combination with other therapeutic agents, either simultaneously or sequentially, depending on the condition to be treated. Exemplary methods of treatment include the following: (1) identifying an individual being treated or being treated with an anti-BCL-2 agent, such as venetoclax; (2) administering to the individual an anti-CD19 ADC, such as ADCx19; and, optionally, (3) administering to the individual an anti-BCL-2 agent, such as venetoclax, in combination with an anti-CD19 ADC (e.g., simultaneously with the ADC or after the ADC). Examples of treatments and therapies include, but are not limited to, chemotherapy (administration of active agents, including drugs such as chemotherapeutic agents); surgery; and radiation therapy. A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer, regardless of mechanism of action. Classes of chemotherapeutic agents include, but are not limited to, alkylating agents, antimetabolites, spindle poison plant alkaloids, cytotoxic / antitumor antibiotics, topoisomerase inhibitors, antibodies, photosensitizers, and kinase inhibitors. Chemotherapeutic agents include compounds used in "targeted therapy" as well as compounds used in conventional chemotherapy.
[0132] Examples of chemotherapeutic agents include the following: lenalidomide (REVLIMID®, Celgene), vorinostat (ZOLINZA®, Merck), panobinostat (FARYDAK®, Novartis), mocetinostat (MGCD0103), everolimus (ZORTRESS®, CERTICAN®, Novartis), bendamustine (TREAKISYM®, RIBOMUSTIN®, LEVACT®, TREANDA®, Mundipharma International), erlotinib (TARCEVA®, Genentech / OSI Pharma), docetaxel (TAXOTERE®, Sanofi-Aventis), 5-FU (fluorouracil, 5-fluorouracil, CAS No. 51-21-8), gemcitabine (GEMZAR®, Lilly), PD-0325901 (CAS No. 391210-10-9, Pfizer), cisplatin (cis-diamine, dichloroplatinum(II), CAS No. 15663-27-1), carboplatin (CAS No. 41575-94-4), paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton), trastuzumab (HERCEPTIN®, Genentech), temozolomide (4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide) CAS No. No. 85622-93-1, TEMODAR®, TEMODAL®, Schering-Plough, tamoxifen ((Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine, NOLVADEX®, ISTUBAL®, VALODEX®, and doxorubicin (ADRIAMYCIN®), Akti-1 / 2, HPPD, and rapamycin.
[0133] Further examples of chemotherapeutic agents include oxaliplatin (ELOXATIN®, Sanofi), bortezomib (VELCADE®, Millennium Pharm), Sutent (SUNITINIB®, SU11248, Pfizer), letrozole (FEMARA®, Novartis), imatinib mesylate (GLEEVEC®, Novartis), XL-518 (Mek inhibitor, Exelixi, WO 2007 / 04515), ARRY-886 (Mek inhibitor, AZD6244, Array BioPharma, AstraZeneca), SF-1126 (PI3K inhibitor, Semaphore Pharmaceuticals), BEZ-235 (PI3K inhibitor, Novartis), XL-147 (PI3K inhibitor, Exelixi), PTK787 / ZK 222584 (Novartis), fulvestrant (FASLODEX®, AstraZeneca), leucovorin (folinic acid), rapamycin (sirolimus, RAPAMUNE®, Wyeth), lapatinib (TYKERB®, GSK572016, GlaxoSmithKline), lonafaribin (SARASAR®, SCH 66336, Schering-Plough), sorafenib (NEXAVAR®, Bayer Labs), gefitinib (IRESSA®, AstraZeneca), irinotecan (CAMPTOSAR®, CPT-11, Pfizer), tipifarnib (ZARNESTRA™, Johnson & Johnson), ABRAXANE™ (Cremophor Free), albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumburg, IL), vandetanib (rINN, ZD6474, ZACTIMA®, AstraZeneca), chlorambucil, AG1478, AG1571 (SU 5271; Sugen), temsirolimus (TORISEL®, Wyeth), pazopanib (GlaxoSmithKline), canfosfamide (TELCYTA®, Teriq), thiotepa and cyclophosphamide (CYTOXAN®, NEOSAR®), alkylsulfonates such as busulfan, imposulfan, and piposulfan;Azirines such as benzodopa, carboquone, metholedopa and uredopa; ethylenimines and methylamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylmelamine; acetogenins (especially bullatacin and bullatacinone); camptothecins (including the synthetic analogue topotecan); bryostatin; kallistatin; CC-1065 (including the synthetic analogues adzercin, carzercin and bizercin); cryptophycins (especially cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycins (synthetic analogues, KW-2189 and CB1-T M1); eleutherobin; pancratistatin; sarcoditin; spongiostatin; nitrogen mustards such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride oxide, melphalan, novebiquine, phenesterin, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and rannustine; enediyne antibiotics (e.g., antibodies such as calicheamicin, calicheamicin gamma 1I, and calicheamicin omega I1 (Angew Chem. Intl. Engl. 1994 33:183-186); dynemicin, dynemicin A; bisphosphonates such as clodronate; esperamine;as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomycin, actinomycin, autramycin, azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, Mitomycins such as esorubicin, idarubicin, nemorubicin, marcelomycin, and mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, porfiromycin, puromycin, queramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; metabolic antagonists such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, and trimetrexate; Purine analogues such as darabin, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens such as calsterone, dromostanol propionate, epithiostanol, mepitiostane, and testolactone; antiadrenal agents such as aminoglutethimide, mitotane, and trilostane; furoic acid supplements such as furoic acid; aceglatone; aldophosphamide glycosyl do;aminolevulinic acid;eniluracil;amsacrine;bestrabulil;bisantrene;edatraxate;defofamine;demecolcine;diaziquone;elfornitine;elliptinium acetate;epothilone;etoglucide;gallium nitrate;hydroxyurea;lentinan;lonidanine;maytansinoids such as maytansine and ansamitocin;mitoguazone;mitoxantrone;mopidanmol;nitraelin;pentostatin;fenameth;pirarubicin;rosantrone;podophyllic acid;2-ethylhydrazide;procarbazine;PSK® polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; schizophyllan; spirogermanium; tenuazonic acid; triazicon, 2,2'; ,2"-Trichlorotriethylamine;trichothecenes (especially T-2 toxin, veracrine A, roridin A and anguidin);urethane;vindesine;dacarbazine;mannomustine;mitobronitol;mitolactol;pipobroman;gacytosine;arabinosides ("Ara-C");cyclophosphamide;thiotepa;6-thioguanine;mercaptopurine;methotrexate;platinum analogues such as cisplatin and carboplatin;vinblastine;etoposide (VP-16) ; ifosfamide; mitoxantrone; vincristine; vinorelbine (NAVELBINE®); novantrone; teniposide; edatrexate; daunomycin; aminopterin; capecitabine (XELOD®, Roche); ibandronic acid; CPT-11; the topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; and pharma- ceutical acceptable salts, acids, and derivatives of any of the above. Drugs such as CHP (doxorubicin, prednisone, cyclophosphamide) or CHOP (doxorubicin, prednisone, cyclophosphamide, vincristine) may be used in combination.
[0134] In addition, the term "chemotherapeutic agent" also includes the following: (i) anti-hormonal drugs that act to regulate or inhibit hormone action on tumors, such as antiestrogens and selective estrogen receptor modulators (SERMs), such as tamoxifen (including NOLVADEX®, tamoxifen citrate), raloxifene, droxifene, 4-hydroxytamoxifen, trioxyfene, ketoxifene, LY117018, onapristone, and FARESTON® (toremifene citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as 4(5)-imidazole, aminoglutethimide, MEGASE® (megestrol acetate), AROMASIN® (exemestane, Pfizer, formestany, famestany, fadrozole, RIVISOR® (vorozole), FEMARA® (letrozole; Novartis), and ARIMIDEX® (anastozole; Novartis); (iii) antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide, goserelin, and troxacitabine (1,3-dioxolane nucleoside cytosine analogue); (iv) protein kinase inhibitors such as MEK inhibitors (WO 2007 / 04515); (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly those that inhibit the expression of genes in signal transduction pathways involved in abnormal cell proliferation, e.g., PKC-α, Raf and H-Ra. s, for example, oblimersen (GENASENSENSE®, Genta Corporation); (vii) ribozymes such as VEGF expression inhibitors (e.g., ANGIOZYME®) and HER2 expression inhibitors; (viii) gene therapy vaccines, for example, ALLOVECTIN®, LEUCTIN® and VAXID®, PROLEUKIN® rIL-2, topoisomerase 1 inhibitors, for example, LURTOTECAN®, ABARELIX® rmRH;(ix) Antiangiogenic agents, such as bevacizumab (AVASTIN®, Genentech), and pharma- ceutically acceptable salts, acids, and derivatives of any of the above;
[0135] Also included as specific "chemotherapeutic agents" are therapeutic antibodies such as alemtuzumab (Campath), bevacizumab (AVASTIN®, Genentech), cetuximab (ERBITUX®, ImClone), panitumumab (VECTIBIX®, Amgen), pertuzumab (PERJETM, OMNITARG™, 2C4, Genentech), trastuzumab (HERCEPTIN®, Genentech), MDX-060 (Medarex), and the antibody-drug conjugate gemtuzumab ozogamicin (MYLOTARG®, Wyeth).
[0136] Humanized monoclonal antibodies with therapeutic potential as chemotherapeutic agents for use in combination with the conjugates of the present disclosure include alemtuzumab, apolizumab, acelizumab, atlizumab, bapineuzumab, bevacizumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, cetrizumab pegol, cidofusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, Examples of such agents include motavizumab, motavizumab, natalizumab, nimotuzumab, norobizumab, numavizumab, omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab, pertuzumab, pesetelizumab, ralizumab, reslizumab, resivizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan, tadocizumab, talizumab, tetribazumab, tocilizumab, toralizumab, trastuzumab, tucotuzumab, celmoleukin, tucusituzumab, umavituzumab, urtoxazumab, and visilituzumab.
[0137] The composition according to the present disclosure is preferably a pharmaceutical composition. The pharmaceutical composition according to and for use in the present disclosure may comprise the active ingredient, i.e., the conjugate compound, and pharma- ceutically acceptable excipients, carriers, buffers, stabilizers, or other materials known to those skilled in the art. Such materials should be non-toxic and not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other materials will depend on the route of administration, either oral, or, for example, cutaneous, subcutaneous, or intravenous injection.
[0138] The pharmaceutical composition for oral administration may be a tablet, a capsule, a powder or a liquid. Tablets may contain a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally contain a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Saline, dextrose or other sugar solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included. Capsules may contain a solid carrier such as gelatin.
[0139] For intravenous, cutaneous or subcutaneous injection, or injection into an affected area, the active ingredient will be in the form of a parenterally acceptable aqueous solution that is pyrogen-free and has appropriate pH, isotonicity and stability. Those skilled in the art can prepare suitable solutions using isotonic vehicles such as, for example, Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection, etc. Preservatives, stabilizers, buffers, antioxidants and / or other additives may be included as necessary.
[0140] [Dosage (dosage)] It will be understood by those skilled in the art that suitable dosages (doses) of anti-CD19 ADCs and / or anti-BCL-2 agents, and compositions containing these active ingredients, will vary from subject to subject. Determining optimal dosages generally requires balancing the level of therapeutic benefit against risk or adverse side effects. The selected dosage level will depend on a variety of factors, including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of treatment, other drugs, compounds, and / or substances used in combination, the severity of the condition, and the species, sex, age, weight, condition, general condition, and medical history of the subject. The amount and route of administration of the compound are ultimately at the discretion of the physician, veterinarian, or clinician, but generally the dosage will be selected to achieve a local concentration at the site of action that achieves the desired effect without inducing substantial adverse or dramatic side effects.
[0141] In some embodiments, the dose of anti-CD19 ADC is determined by the expression of CD19 observed in a sample obtained from a subject. That is, the level or location of expression of CD19 in a sample can be an indication that a higher or lower dose of anti-CD19 ADC is required. For example, a high expression level of CD19 can indicate that a higher dose of anti-CD19 ADC is appropriate. In some cases, a high expression level of CD19 can indicate that administration of anti-CD19 ADC and other agents is required. For example, combined administration of anti-CD19 ADC with a chemotherapeutic agent. A high expression level of CD19 suggests a more aggressive therapy.
[0142] In some embodiments, the dose of anti-BCL-2 agent is determined by the expression observed in a sample obtained from the subject. That is, the level or location of expression in the sample may indicate that a higher or lower dose of anti-BCL-2 agent is required. For example, a high level of BCL-2 expression may indicate that a higher dose of anti-BCL-2 agent is appropriate. In some cases, a high level of BCL-2 expression may indicate that administration of an anti-BCL-2 agent and another agent is required. For example, combined administration of an anti-BCL-2 agent and a chemotherapeutic agent. A high level of BCL-2 expression may indicate a more aggressive therapy.
[0143] Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be effected, with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
[0144] In general, a suitable dosage of each active compound will be in the range of about 100 ng to about 25 mg (more typically about 1 μg to about 10 mg) per kg of subject body weight per day. Where the active compound is a salt, an ester, an amide, a prodrug, or the like, the amount administered is calculated on the basis of the parent compound and the actual amount to be used is increased proportionately. In one embodiment, each active compound is administered to a human subject according to the following dosage regimen: about 100 mg, three times daily. In one embodiment, each active compound is administered to a human subject according to a regimen of about 150 mg, twice daily. In one embodiment, each active compound is administered to a human subject according to a regimen of about 200 mg, twice daily.
[0145] However, in one embodiment, each conjugate compound is administered to a human subject according to the following dosage regimen: about 50 mg or about 75 mg, 3 or 4 times per day. In one embodiment, each conjugate compound is administered to a human subject at a dosing regimen of about 100 mg or about 125 mg, twice daily. For anti-CD19 ADCs that are PBD bearing ADCs, the above dosage amounts can apply to an effective amount of the PBD compound that results in a conjugate (including the PBD moiety and a linker to the antibody) or the amount of compound released, for example, after cleavage of the linker.
[0146] The anti-CD19 ADC comprises an anti-CD19 antibody. The anti-CD19 antibody may be an RB4v1.2 antibody. The ADC may comprise a drug that is a PBD dimer. The anti-CD19-ADC may be ADCx19. The ADC may be an ADC disclosed in US Pat. No. 6,399,633. The anti-BCL-2 agent may be venetoclax (ABT-1999), navitoclax (ABT-263), ABT-737, S55746 / BCL201, and oblimersen (G3139). Preferably, the anti-BCL-2 agent is venetoclax (ABT-1999).
[0147] 〔antibody〕 The term "antibody" herein is used in the broadest sense and specifically encompasses monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), intact antibodies (also described as "full-length" antibodies) and antibody fragments, so long as they exhibit the desired biological activity, e.g., the ability to bind to CD19. (Miller et al (2003) Jour. of Immunology 170:4854-4861). Antibodies may be murine, human, humanized, chimeric, or derived from other species, such as rabbit, goat, sheep, horse, or camel.
[0148] Antibodies are proteins produced by the immune system that can recognize and bind to specific antigens. (Janeway, C., Travers, P., Walport, M., Shlomchik (2001) Immuno Biology, 5th Ed., Garland Publishing, New York).
[0149] A target antigen generally has multiple binding sites, also called epitopes, that are recognized by complementarity determining regions (CDRs) on multiple antibodies. Antibodies that specifically bind to different epitopes have different structures; that is, an antigen has more than one corresponding antibody. An antibody may comprise a full-length immunoglobulin molecule or an immunologically active portion of a full-length immunoglobulin molecule, i.e., a molecule that contains an antigen-binding site or portion thereof that immunospecifically binds to an antigen of an associated target, such as, but not limited to, a cancer cell or a cell that produces an autoimmune antibody associated with an autoimmune disease. The immunoglobulin can be of any system (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclass, or allotype (e.g., human G1m1, G1m2, G1m3, non-G1m1 [i.e., any allotype other than G1m1], G1m17, G2m23, G3m21, G3m28, G3m11, G3m5, G3m13, G3m14, G3m10, G3m15, G3m16, G3m6, G3m24, G3m26, G3m27, A2m1, A2m2, Km1, Km2, and Km3). The immunoglobulins may be from any species, including from human, mouse, or rabbit.
[0150] An "antibody fragment" includes a portion of a full-length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, and scFv fragments; diabodies; linear antibodies; fragments produced by Fab expression libraries, anti-idiotypic (anti-Id) antibodies, CDRs (complementarity determining regions), and epitope-binding fragments of any of the above that immunospecifically bind to cancer cell antigens, viral or microbial antigens, single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for naturally occurring mutations that may be present in minor amounts.
[0151] Monoclonal antibodies are highly specific, being directed against one antigenic epitope. Furthermore, in contrast to polyclonal antibody preparations which contain different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. Monoclonal antibodies are advantageous in that they can be synthesized uncontaminated by other antibodies. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with the present disclosure may be made by the hybridoma method first described by Kohler et al. (1975) Nature 256:495, or by recombinant DNA methods (see U.S. Pat. No. 4,816,567). The monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson et al (1991) Nature, 352:624-628; Marks et al (1991) J. Mol. Biol., 222:581-597, or from transgenic mice carrying a fully human immunoglobulin system (Lonberg (2008) Curr. Opinion 20(4):450-459).
[0152] The monoclonal antibodies herein specifically include "chimeric" antibodies in which portions of the heavy and / or light chains are identical to or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chains are identical to or homologous to corresponding sequences in other antibodies derived from other species or belonging to other antibody classes or subclasses, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et al (1984) Proc. Natl. Acad. Sci. USA, 81:6851-6855). Chimeric antibodies include "primatized" antibodies that contain variable domain antigen-binding sequences derived from a non-human primate (e.g., an Old World monkey or ape) and human constant region sequences.
[0153] A "complete antibody" herein comprises a VL domain and a VH domain, as well as a light chain constant domain (CL) and a heavy chain constant domain (CH1, CH2 and CH3). The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof. A complete antibody may have one or more "effector functions", which refer to biological activities attributable to the Fc region (native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include C1q binding; complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and down-regulation of cell surface receptors such as the B cell receptor and BCR.
[0154] Depending on the amino acid sequence of the constant domain of their heavy chains, intact antibodies can be assigned to different "classes". There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into "subclasses" (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy chain constant domains that correspond to the various classes of antibodies are called α, δ, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.
[0155] BRIEF DESCRIPTION OF THE DRAWINGS Embodiments and experiments illustrating the principles of the present disclosure are now discussed with reference to the accompanying drawings. [Brief description of the drawings]
[0156] [Figure 1]The present disclosure includes combinations of the described aspects and preferred features, unless such combinations are expressly not permitted or explicitly avoided. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. Aspects and embodiments of the present disclosure are illustratively illustrated with reference to the accompanying drawings. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference. Unless otherwise required by context, the term "comprises" and variations thereof throughout this specification, including the following claims, are understood to mean the inclusion of a recited integer, step, or group of integers or steps, but not the exclusion of an integer, step, or group of integers or steps. It should be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Ranges can be expressed herein as "about" from one particular value and / or "about" from another particular value. When a range is expressed, another embodiment includes the one particular value and / or the other particular value. Similarly, when values are expressed as approximations, by use of "about," it will be understood that the particular value forms another embodiment.
[0157] Some embodiments The following paragraphs set forth some specific embodiments of the present disclosure. 1. A method of selecting an individual suitable for treatment with ADCx19, or ADCT-402, wherein the individual is selected for treatment with ADCx19 or ADCT-402 if the individual has been treated with venetoclax. 2. A method of selecting an individual suitable for treatment with ADC×19 or ADCT-402, wherein the individual is selected for treatment with ADC×19 or ADCT-402 if the individual is undergoing treatment with venetoclax. 3. The method of any one of the above paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with venetoclax. 4. A method for treating a condition in an individual, comprising: (i) selecting an individual suitable for treatment with the method according to any one of paragraphs 1 to 3 above; and (ii) administering to the individual an effective amount of ADCx19 or ADCT-402. 5. The method of paragraph 4, further comprising administering ADCx19 or ADCT-402 in combination with Venetoclax. 6. A method for treating a condition in an individual, comprising administering to the individual an effective amount of ADCx19 or ADCT-402 and venetoclax. 7. The method of paragraph 6, wherein the individual is selected for treatment with the method of any one of paragraphs 1-3. 8. The method of any one of paragraphs 5 to 7, wherein the treatment comprises administering ADCx19 or ADCT-402 prior to, concurrently with, or after venetoclax. 9. The method of any preceding paragraph, wherein the treating further comprises administering a chemotherapeutic agent. 10. The method of any preceding paragraph, wherein the individual is a human. 11. The method of any preceding paragraph, wherein the individual has or has been determined to have a condition. 12. The method of paragraph 11, wherein the individual has been determined to have or have a cancer that expresses CD19+ or CD19+ tumor-associated non-tumor cells (such as CD19+ infiltrating cells). 13. The method of any of the preceding paragraphs, wherein the individual is undergoing treatment with venetoclax. 14. The method of any of the preceding paragraphs, wherein the individual has been treated with venetoclax. 15. The method of any of the preceding paragraphs, wherein the individual is resistant to treatment with venetoclax or a further treatment. 16. The method of any of the preceding paragraphs, wherein the treatment has increased efficacy compared to monotherapy with either ADCx19 or ADCT-402 or venetoclax. 17. The method of any of the preceding paragraphs, wherein the condition is a proliferative disease. 18. The method of any preceding paragraph, wherein the condition is cancer. 19. The method of paragraph 18, wherein the condition is selected from the group including proliferative diseases, e.g. non-Hodgkin's lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and leukemias, such as hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and acute lymphoblastic leukemia (ALL), such as Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL). 20. ADCx19 or ADCT-402 used in any of the methods described in paragraphs 4 to 19. 21. A composition comprising ADCx19 or ADCT-402, for use in the treatment method described in any one of paragraphs 4 to 19. 22. Venetoclax for use in a method of treatment according to any one of paragraphs 5 to 19. 23. A composition comprising venetoclax for use in a treatment method according to any one of paragraphs 5 to 19. 24. Use of ADCx19 or ADCT-402 in the manufacture of a medicament for treating a condition in an individual, said treatment comprising a method according to any one of paragraphs 4 to 19. 25. Use of venetoclax in the manufacture of a medicament for treating a condition in an individual, said treatment comprising a method described in any one of paragraphs 5 to 19. 26. The following: a first drug comprising ADCx19 or ADCT-402; Any one of paragraphs 4 to 19 includes "a package insert containing instructions for administering said first drug in the manner described; Including the kit. 27. The following: Second-line drugs containing venetoclax 27. The kit of paragraph 26, further comprising: Description of the invention 1. A method of selecting an individual suitable for treatment with an anti-CD19 ADC, wherein the individual is selected for treatment with an anti-CD19 ADC if the individual has been treated with an anti-BCL-2 agent. 2. A method for selecting an individual suitable for treatment with an anti-CD19 ADC, where the individual is selected for treatment with an anti-CD19 ADC if the individual has been treated with an anti-BCL-2 agent. 3. The method of any one of the preceding paragraphs, wherein the individual is selected for said treatment if resistant to treatment or further treatment with the anti-BCL-2 agent. 4. A method for treating a condition in an individual, comprising: (i) selecting an individual suitable for treatment by the method according to any one of 1 to 3 above; and (ii) administering to the individual an effective amount of an anti-CD19 ADC. 5. The method of paragraph 4, wherein the method of treatment further comprises administering the anti-CD19 ADC in combination with an anti-BCL-2 agent. 6. A method of treating a Condition in an individual, comprising administering to the individual effective amounts of an anti-CD19 ADC and an anti-BCL-2 agent. 7. The method of paragraph 6, wherein the individual is selected for treatment with the method of any one of paragraphs 1 to 3. 8. The method of any one of paragraphs 5 to 7, comprising administering an anti-CD19-ADC prior to, simultaneously with, or after the anti-BCL-2 agent. 9. The method of any preceding paragraph, wherein the treating further comprises administering a chemotherapeutic agent. 10. The method of any preceding paragraph, wherein the individual is a human. 11. The method of any preceding paragraph, wherein the individual has or has been determined to have a condition. 12. The method of paragraph 11, wherein the individual has been determined to have or have a cancer that expresses CD19+ or CD19+ tumor-associated non-tumor cells (such as CD19+ infiltrating cells). 13. The method of any preceding paragraph, wherein the individual is undergoing treatment with an anti-BCL-2 agent. 14. The method of any preceding paragraph, wherein the individual has undergone treatment with an anti-BCL-2 agent. 15. The method of any preceding paragraph, wherein the individual is resistant to treatment with an anti-BCL-2 agent or to a further treatment. 16. The method of any preceding paragraph, wherein the treatment has increased efficacy compared to monotherapy with either the anti-CD19-ADC or the anti-BCL-2 agent. 17. The method of any preceding paragraph, wherein the anti-CD19 ADC is ADCx19. 17a. The method of any preceding paragraph, wherein the anti-CD19 ADC is ADCT-402. 18. The method of any of the preceding paragraphs, wherein the condition is a proliferative disease. 19. The method of paragraph 18, wherein the condition is cancer. 20. The method of paragraph 19, wherein the condition is selected from the group including proliferative diseases, e.g. non-Hodgkin's lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and leukemias, such as hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and acute lymphoblastic leukemia (ALL), such as Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL). 21. The method of any of the above paragraphs, wherein the anti-BCL-2 agent is selected from the group consisting of venetoclax (ABT-1999), navitoclax (ABT-263), ABT-737, S55746 / BCL201, and oblimersen (G3139). 22. The method of any of the preceding paragraphs, wherein the anti-BCL-2 agent is venetoclax. 23. An anti-CD19-ADC for use in a method of treatment according to any one of paragraphs 4 to 22. 24. A composition comprising an anti-CD19-ADC for use in a treatment method according to any one of paragraphs 4 to 22. 25. An anti-BCL-2 agent for use in a method of treatment according to any one of paragraphs 5 to 22. 26. A composition comprising an anti-BCL-2 agent for use in a method of treatment according to any one of paragraphs 4 to 22. 27. Use of an anti-CD19 ADC in the manufacture of a medicament for treating a condition in an individual, said treatment comprising a method according to any one of paragraphs 4 to 22. 28. Use of an anti-BCL-2 agent in the manufacture of a medicament for treating a condition in an individual, said treatment comprising a method according to any one of paragraphs 5 to 22. 29. The following: First agent includes anti-CD19 ADC; A kit comprising: "a package insert containing instructions for administering the first agent according to the method described in any one of paragraphs 4 to 22." 30. In addition, the following: 30. The kit of paragraph 29 comprising: a second agent comprising an anti-BCL-2 agent.
[0158] [Example] In the following examples: - CD19 expressing cell lines suitable for use in the examples include Ramos, Daudi, Raji, WSU-DLCL and NALM-6 cells.
[0159] -Disease A-Diffuse large B-cell lymphoma / DLBC is an aggressive non-Hodgkin's lymphoma that arises from the B cells of the lymphatic system. It is the largest subgroup of non-Hodgkin's lymphoma.
[0160] -Disease B-mantle cell lymphoma / MCL is a rare B-cell NHL that is most common in men over 60 years of age. The disease is aggressive (fast-growing), although some patients may progress in a more indolent (slow-growing) manner. MCL accounts for approximately 5% of all NHL.
[0161] -Disease C- Follicular lymphoma / FL is a fairly indolent form of NHL that has a long survival time but is extremely difficult to cure and may transform into a more aggressive lymphoma. Example 1
[0162] In a separate experiment, CD19-expressing cell lines are incubated for 0, 6, 24 and 48 hours with etoposide (negative control) and oxaliplatin (positive control), 1 μg / mL anti-CD19 ADC (ADC targeting CD19 with a PBD dimer warhead), 1 μg / mL anti-CD19 (antibody in the ADC) and 1 μg / mL B12-SG3249 (non-binding control ADC with the same PBD warhead as the anti-CD19 ADC). After incubation, the cells are washed and fed with human dendritic cells (DCs) for an additional 24 hours, after which DC activation is measured by increased surface expression of CD86 on the DC population (measured by flow cytometry) and by measuring DC-mediated release of IL-8 and MIP2. Example 2
[0163] The objective of this study is to evaluate the safety, tolerability, and preliminary pharmacological and clinical activity of this combination therapy. The following types of cancer have been selected for study: Disease A, Disease B, and Disease C There is evidence that both drugs work as monotherapy: Anti-CD19 ADCs (see, for example, WO 2016 / 166298, WO 2014 / 057122, and WO 2016 / 166307) Anti-BCL-2 agents (see KS Peggs et al. 2009, Clinical and Experimental Immunology, 157:9-19 [doi:10.1111 / j.1365-2249.2009.03912.x]) The study will also evaluate whether each combination induces pharmacological changes in tumors that may suggest potential clinical benefit. Furthermore, there will be preliminary evidence that the combination may increase response rates and durability of responses compared with published data on either anti-CD19 ADCs or anti-BCL-2 agents administered alone. Each disease group will include a subset of patients previously treated with an anti-BCL-2 agent, and we will examine whether combination therapies can overcome resistance to anti-BCL-2 therapy. It is not our intention to apply specific molecular selection for each disease, as currently available data do not generally support excluding patients on the basis of an approved molecular diagnostic test.
[0164] Rationale for setting the anti-CD19 ADC starting dose The established RDE for the ADC (ug / kg given every 3 weeks) will be used for all patients in this study. To ensure patient safety, the starting dose used will be below the RDE, but it is the dose at which patient benefit was still demonstrated in Study ADC1, suggesting that patients enrolled at this dose will derive at least some benefit from participation.
[0165] Rationale for setting the starting dose of anti-BCL-2 agents The established RDE for the anti-BCL-2 agent (ug / kg given every 3 weeks) will be used for all patients in this study. To ensure patient safety, the starting dose used will be below the RDE, but is the dose at which patients were still shown to benefit in Study SA1, suggesting that patients enrolled at this dose will derive at least some benefit from participation. Objectives and related evaluation items
[0166] [Table 1] research design This is a Phase Ib, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of an ADC in combination with an anti-BCL-2 agent in patients with disease A, disease B and disease C. The study will consist of a dose escalation portion followed by a dose expansion portion. Dose escalation will begin with a reduced starting dose of both the ADC and the anti-BCL-2 agent (compared to the recommended Phase II dose or the approved dose, respectively) to ensure patient safety. The starting dose will be 33% (or 50%) of the RDE of each compound. The dose of the anti-BCL-2 agent will then be increased first until the RDE or the approved dose is reached, or a lower dose will be administered if necessary for tolerability reasons. The dose of the ADC will then be increased until the RDE of the combination is reached. This is illustrated in the diagram below:
[0167] [Table 2] If the dose combination is determined to be safe, further patient studies may be conducted to confirm safety and tolerability at those doses. The doses of each compound may be further adjusted and / or the regimen may be modified. Dose escalation of the combination therapy is based on a Bayesian logistic regression model (BLRM) based on dose-limiting toxicities (DLTs) observed in the first (or first two) treatment cycles. The use of BLRM is an established method for estimating maximum tolerated doses (MTDs) / extended recommended doses (RDEs) in cancer patients. The adaptive BLRM follows the principle of overdose controlled titration (EWOC) to control the risk of DLTs in future patients participating in the study. The use of Bayesian response adaptive models for small data sets is accepted by the FDA and EMEA (Guideline for Clinical Trials in Small Populations, February 1, 2007) and is supported by a large literature (Babb et al. 1998, Neuenschwander et al. 2008). The investigators and sponsors will determine the new combination dose at the Dose Escalation Safety Call (DESC) based on review of patient tolerability and safety information (including the BLRM summary of DLT risks, if applicable), and PK, PD, and preliminary activity information available at the time of the decision.
[0168] Once the MTD / RDE of the combination has been determined, an expansion portion of the study may be initiated to further evaluate safety, tolerability, and preliminary efficacy. Regarding combination with IO, changes in immune infiltration in tumors will also be characterized following combination treatment in targeted disease indications. Given the clinical experience to date with the agents in this study, it is believed that in many cases combination doses can be identified without testing large doses or dosing schedules. Patients will be instructed to undergo tumor biopsies at baseline and again after approximately two cycles of treatment to assess the pharmacodynamic activity of the combination therapy. Regarding IO combos: The degree of variation in tumor infiltration by immune cells, including lymphocytes and macrophages, contributes to decisions regarding potential benefit.
[0169] Dose Escalation Portion In the dose-escalation phase of the study, a fixed dose of the ADC will be administered intravenously and the dose of the anti-BCL-2 agent will be increased until the RDE of the anti-BCL-2 agent is reached, after which the dose of the ADC will be increased (in different cohorts) while the dose of the anti-BCL-2 agent will be held constant. Approximately 3-4 patients with Disease A, Disease B, or Disease C are treated in each escalation cohort until measurements of the MTD / RDE are determined. A 24-hour observation period will be conducted before the second patient is enrolled in dose level 1. The DLT observation period at each dose level will be either 1 cycle (3 weeks) or 2 cycles (6 weeks) as mandated by the competent authorities for IO treatment, after which a decision will be made to escalate to the next dose level in the next cohort, remain at the current dose level, or taper to the previous dose level. There will be no tapers from dose level 1. Dose escalation will not be permitted. Dose escalation will not be permitted at any dose level unless complete DLT information is available for at least two patients by the first cycle. Dose escalation will be determined using mCRM with a target DLT rate of 30% and an equivalence interval of 20% to 35%, with dose escalation-overdose control (EWOC) and no dose skipping.
[0170] Patients will be assigned to actively enrolling cohorts. Dose escalation will be performed for each combination after one cycle of treatment. Safety assessments, including adverse events and laboratory values, will be closely monitored for all enrolled patients to identify DLTs. A single MTD / RDE will be defined; no disease-specific MTD / RDE will be established. mCRM is performed for DE under the oversight of the Dose Escalation Steering Committee (DESC). The DESC reviews each escalation dose after reviewing all available safety data. Decisions are also informed by PK data from patients at that dose level and the previous dose level. The DESC may stop dose escalation prior to the MTD determination based on emerging PK, PD, toxicity, or response data. If at least one patient in the study achieves at least a partial response, or if the DESC determines that further evaluation of PK or PD data is necessary to determine the RDE, additional patients may be enrolled at any dose to further evaluate safety and tolerability. Dose escalation will be stopped after three consecutive cohorts (or at least six patients) have been randomized to the same dose level. If the MTD is not reached, a recommended dose for escalation (RDE) will be determined. A minimum of six patients must be treated with the combination before determining the MTD / RDE. It is intended that patients will undergo paired tumor biopsies during dose escalation, and analysis of these biopsies will allow for a better understanding of the relationship between dose and pharmacodynamic activity of the combination therapy.
[0171] Safety monitoring by the dose escalation steering committee The DESC, consisting of ADC Therapeutics and the investigators, will continually review patient safety during DE to determine if modifications to the mCRM-defined dose escalation schedule are necessary. In addition to safety observations, pharmacokinetic and / or pharmacodynamic data will also inform decision making. Intermediate doses may be assigned with consensus between ADC Therapeutics and the investigators. The DESC may continue to provide oversight during Part 2. A formal Data Safety Monitoring Board (DSMB) will not be used.
[0172] Dose expansion portion Once the MTD / RDE has been declared, the dose expansion portion may be initiated. The primary objective of the expansion portion is to further evaluate the safety and tolerability of the investigational drug at the MTD / RDE and to obtain a preliminary understanding of the efficacy of the combination therapy compared with existing data on the efficacy of the single agents. One of the key exploratory objectives is the evaluation of changes in intratumoral immune infiltration in response to treatment. This will be assessed in paired tumor biopsies taken from patients treated at MTD / RDE, combining at least 10 evaluable biopsies (biopsy specimens must contain sufficient tumor for analysis). If this is not possible, collection of said biopsy tissue may be discontinued. At least 10-20 patients are planned to be treated in each study arm. There will be multiple different arms, one treatment arm per disease. For dose expansion, a total of nine arms may be established. If any arm cannot be enrolled, enrollment in that arm may be discontinued before the goal of 10-20 patients is reached. Up to approximately six patients in each arm who have progressed on a single prior (i.e., unconjugated) anti-BCL-2 therapy will be permitted to be treated, with this number potentially increased if the combination shows promise in overcoming prior resistance to a single anti-BCL-2 therapy.
[0173] Patient population The study will be conducted in adult patients with advanced disease A, B, or C, as described above. The investigator or designee must ensure that only patients who meet all of the following inclusion criteria and none of the exclusion criteria will be treated in the study.
[0174] Selection Criteria Patients eligible for inclusion in this study had to meet all of the following criteria: 1. Written consent must be obtained prior to the procedure 2.18 years old.
[0175] 3.Patients with advanced / metastatic cancer with measurable disease by RECIST version 1.1, patients who have progressed despite or are intolerant to standard treatment, or patients for whom no standard treatment exists. Patients must be in one of the following groups: Disease A Disease B Disease C 4. ECOG Performance Status 0-1 (or 2 TBC) 5. TBC: Patients must have a lesion suitable for biopsy and be candidates for tumor biopsy according to the guidelines of the treatment institution. Patients must be willing to undergo a new tumor biopsy at baseline and during the treatment period of this study. 6. Prior treatment with an anti-BCL-2 agent or related compound (i.e., same MOA) is permitted.
[0176] Exclusion criteria Patients eligible for this study must not meet any of the following criteria: Exclusion criteria Patients eligible for this study must not meet any of the following criteria: 1. History of severe hypersensitivity reactions to other monoclonal antibodies (same backbone monoclonal antibody as the ADC or same IO monoclonal antibody, if applicable) 2. Known history of seropositive ADA to the monoclonal antibody backbone as well as the ADC 3. Central nervous system (CNS) disease only (if applicable) 4. Evidence of symptomatic CNS metastases or leptomeningeal disease (brain MRI or previously confirmed cerebrospinal fluid (CSF) cytology) Previously treated asymptomatic CNS metastases are permitted, provided that last line of treatment (systemic anticancer therapy and localized radiation therapy) was completed ≥8 weeks prior to the start of treatment; however, tapering of low-dose steroids is permitted. Patients with isolated dural metastasis are eligible 5.Patients with laboratory values outside the following ranges: Serum creatinine ≤ 1.5 x ULN. If serum creatinine > 1.5, patients must have creatinine clearance (calculated using the Cockcroft-Gault formula or measured) > 60 mL / min / 1.73 m2 to be eligible Total bilirubin > 1.5 times the upper limit of normal (ULN), except for cases where total bilirubin > 3.0 times the ULN or direct bilirubin > 1.5 times the ULN. Patients with alanine aminotransferase (ALT) levels >3x the upper limit of normal, except for patients with liver tumor infiltration and ALT levels >5x the upper limit of normal. Patients with aspartate aminotransferase (AST) >3x the upper limit of normal, except for patients with tumor infiltration of the liver. Patients with AST >5x the upper limit of normal were excluded. Absolute neutrophil count < 1.0 x 10e9 / L ·Platelet count<75×10e9 / L Hemoglobin (Hgb) < 8g / dL Potassium, magnesium, calcium or phosphate abnormalities >CTCAE grade 1 despite appropriate replacement therapy 6. Cardiac dysfunction or clinically significant cardiac disease, including any of the following: Clinically significant and / or uncontrolled cardiac disease, such as congestive heart failure requiring treatment (NYHA grade III or IV) or uncontrolled hypertension defined as a systolic blood pressure (SBP) of 160mmHg and / or a diastolic blood pressure (DBP) of 100mmHg, with or without concomitant antihypertensive medications QTcF > 470 msec (women) or > 450 msec (men) on screening electrocardiogram using Fridericia correction (congenital long QT syndrome) Acute myocardial infarction or unstable angina less than 3 months prior to study enrollment Valvular disease with clinically significant cardiac dysfunction Symptomatic pericarditis -History or ongoing cardiomyopathy Left ventricular ejection fraction (LVEF) < 40% measured by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan History or presence of clinically significant cardiac arrhythmias, including ventricular, supraventricular, nodal arrhythmias, and conduction abnormalities (TBC modifier: pacemaker required or not controlled by medical therapy) Presence of unstable atrial fibrillation (ventricular response rate >100 bpm) Note: Patients with stable atrial fibrillation may be enrolled as long as they do not meet other cardiac exclusion criteria. Complete left bundle branch block (LBBB), bifascicular block Any clinically significant ST-segment and / or T-wave abnormalities 7. Treatment was discontinued due to toxicity from previous IO therapy. Patients who were adequately treated with replacement therapy for drug-related skin rash or endocrine disorders are not excluded, provided that the toxicity did not lead to discontinuation of the previous treatment. 8. Patients with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes, residual hypothyroidism due to an autoimmune disease requiring only hormone replacement, psoriasis not requiring systemic treatment, or disease not expected to recur in the absence of an external trigger will be allowed to enroll only if the trigger can be avoided. 9. Human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection Testing is not required to be eligible. HCV testing should be considered if the patient is at risk for undiagnosed HCV (e.g., history of injection drug use). 10. Malignant disease other than that treated in this study. Exceptions to this exclusion include malignancies that have been curatively treated and have not recurred within 2 years prior to study treatment, completely resected basal cell and squamous cell skin cancers, malignancies that were considered indolent and did not require treatment, and completely resected carcinoma in situ. 11. Systemic anti-cancer therapy within 2 weeks of first dose of investigational drug. For cytotoxic agents with significant delayed toxicity, such as mitomycin C and nitrosoureas, a washout period of 4 weeks is indicated. For patients receiving anti-cancer immunotherapy, such as CTLA-4 antagonists, a drug holiday period of 6 weeks is indicated. 12. Active diarrhea CTCAE grade 2 or diseases accompanied by chronic diarrhea (irritable bowel syndrome, inflammatory bowel disease, etc.) 13.Presence of CTCAE grade 2 toxicity (excluding alopecia, peripheral neuropathy, and ototoxicity, but excluding CTCAE grade 3 or higher) 14. Active infection requiring systemic antibiotic therapy 15. Active ulcer or gastrointestinal bleeding in the upper gastrointestinal tract 16. Active bleeding diathesis or oral anti-vitamin K drugs (excluding low-dose warfarin and aspirin or equivalent, if INR is 2.0 or less) 17. Active autoimmune disease, motor neuropathy thought to be of autoimmune origin, and other central nervous system autoimmune diseases 18.Patients who require concomitant use of immunosuppressants or long-term administration of corticosteroids: Replacement dose steroids in the setting of adrenal insufficiency Topical steroids, inhalants, eye drops, eye drops 19. Use of live vaccines against infectious diseases (influenza, chickenpox, pneumococcus, etc.) within 4 weeks after starting the study drug administration (use of live vaccines is not permitted throughout the study period) 20. Use of hematopoietic colony-stimulating factors (G-CSF, GMCSF, M-CSF, etc.) (less than 2 weeks prior to the start of administration of the investigational drug). Erythroid stimulating agents may be used if they are started at least 2 weeks prior to the first administration of the investigational drug. 21.Major surgery within 2 weeks of first dose of study drug (NB mediastinoscopy, insertion of a central venous access device, or insertion of a feeding tube are not considered major surgery) 22.Radiation therapy within 2 weeks of first dose of investigational drug, except for palliative radiation therapy to limited fields such as for the treatment of tun 1 or masses with bone pain or localized pain. Patients must have measurable residual disease that has not been irradiated to allow for response to treatment assessment. 23. Participation in an interventional clinical trial within 2 weeks of first administration of the investigational drug 24.A medical condition that, in the opinion of the investigator, may prevent the patient from participating in the clinical trial due to safety concerns, compliance with clinical trial procedures, or interpretation of study results. 25. Sexually active men will not father a child during this period unless they use condoms during sexual intercourse and for 90 days after stopping study drug treatment. Condoms should also be used by men who have had a vasectomy to prevent semen-mediated drug delivery.
[0177] 26. Pregnant or lactating women with a confirmed positive hCG test, with pregnancy defined as a woman's condition after conception until the end of pregnancy. In rare cases of endocrine tumors, hCG levels may be above the normal range, but the patient is not pregnant. In such cases, a repeat serum hCG test (with non-elevated results) and vaginal / pelvic ultrasound should be performed to exclude pregnancy. After reviewing the results and discussing with the Medical Reference, these patients may be included in the study. 27. Females of childbearing potential. This is defined as any female of physiological reproductive potential who is not using a highly effective method of contraception during treatment with the study drug and for 90 days after the last dose of the study drug. Highly effective methods of contraception include: Complete abstinence (when this is consistent with the patient's desired usual lifestyle. Periodic abstinence (e.g., calendar, ovulation, symptom-temperature, postovulation methods) and abstinence are not acceptable methods of contraception. Female sterilization (surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation ≥6 weeks prior to receiving study treatment. In the case of oophorectomy alone, only if the female's reproductive status was confirmed by follow-up hormone level evaluation. Male sterilization (at least 6 months prior to screening). For female patients, the vasectomized male partner must be the patient's only partner. Use of oral (estrogen and progesterone), combined hormone therapy administered as an injected or implanted intrauterine device (IUD) or intrauterine device (IUS), or other hormonal contraceptive methods with comparable efficacy (failure rate <1%) (e.g., hormonal vaginal ring or transdermal hormonal contraceptive methods). If oral contraceptives were used, women had to have taken the same pills for at least 3 months before receiving the study drug. Women with 12 months of spontaneous amenorrhea and an appropriate clinical profile (e.g., appropriate age, history of vasomotor symptoms) or who have had bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks previously are considered to be of no childbearing potential. In cases of oophorectomy alone, a woman is considered to be of no childbearing potential only if follow-up hormone level evaluation has confirmed her reproductive status.
[0178] Dose-limiting toxicities and dose modification guidelines Dose-limiting toxicity (DLT) is defined as any of the following events that, in the opinion of the investigator, are considered at least possibly related to the ADC during the 21-day DLT evaluation period. Toxicities clearly and directly related to the primary disease or other etiology are excluded from this definition.
[0179] Definition of DLT Hematological DLTs are defined as follows: Grade 3 or 4 febrile neutropenia or neutropenic infection Grade 4 neutropenia lasting more than 7 days Grade 4 thrombocytopenia Grade 3 thrombocytopenia associated with clinically significant bleeding or requiring platelet transfusion Grade 3 anemia requiring transfusion Grade 4 anemia Non-hematologic DLTs are defined as follows: Grade 4 non-hematologic toxicity Grade 3 non-hematologic toxicity lasting more than 3 days despite optimal supportive care or medical intervention Hy's rule (AST and / or ALT >3x ULN, bilirubin >2x ULN, no early evidence of cholestasis (serum alkaline phosphatase (ALP) activity <2x ULN), and no other reason to explain the elevated transaminases and serum total bilirubin (viral hepatitis A, B, C, pre-existing or acute liver disease, other drugs that may cause the observed damage, etc.) Grade 3 or greater hypersensitivity / infusion-related reaction (regardless of premedication). Grade 3 hypersensitivity / infusion-related reactions that resolve with appropriate clinical management within 8 hours of onset are not considered DLTs. Ejection fraction <40% or >20% decrease from baseline Grade 4 tumor lysis syndrome (grade 3 TLS does not constitute a DLT unless it leads to irreversible end-organ damage) The following conditions are not considered non-hematologic DLTs: Grade 3 fatigue within 7 days Grade 3 diarrhea, nausea, or vomiting that responds to treatment and improves by at least one grade within 3 days for Grade 3 adverse events, and within 7 days for Grade 1 or less adverse events, in the absence of prior medication - AST or ALT elevation is 5 times or more the upper limit of normal, but is 8 times or less the upper limit of normal, without an increase in bilirubin, and decreases to Grade 2 or less within 5 days after onset Grade 3 serum lipase or serum amylase ≤7 days in the absence of clinical signs or symptoms of pancreatitis.
[0180] Patients who experience a DLT that resolves or stabilizes with appropriate medical management may continue treatment at the discretion of the investigator, in consultation with the sponsor.
[0181] Dose Modification Guidelines for the management of specific toxicities are detailed in the table below. For management of events not specified in the table, the following may provide guidance to investigators:
[0182] [Table 3] Example 3
[0183] method MTT proliferation assay of cell lines exposed (96 h) to increasing ADCx19 concentrations and calculation of IC50. Pearson correlation (r): IC50 was calculated for cell surface CD19 expression levels (absolute fluorescence quantification with Quantum Simple Cell Microspheres; data from PMID 29298756) and RNA levels (Illumina HT-12 array and HTG EdgeSeq Oncology Biomarker Panel data from PMID 29066507). Synergy at 96 h was assessed by Chou-Talalalay combination index (CI) (synergy CI<0.9, additivity CI=0.9-1.1, antagonism / ineffectiveness CI>1.1) against two activated B-cell-like (ABC) DLBCL (OCI-LY-3, TMD8) and two germinal center (GCB) DLBCL (VAL, WSU-DLCL2).
[0184] result The ADCx19 median IC50 was 4 pM (95% CI, 2-10 pM) in 48 B cell lymphoma lines and over 800-fold higher in 9 T cell lymphoma lines (3.5 nM; 95% CI, 0.8-11 nM), as expected based on CD19 expression patterns. Focusing on B cell lymphomas, in vitro activity correlated with target expression measured at the cell surface protein level [(absolute quantification, n = 40, r-0.37 P0.02; non-absolute quantification, n = 42, -0.48, P0.001) and RNA level [(array, n = 39, -0.69 P<0.001; HTG, n = 31, -0.73 P0.001)]. In DLBCL, the presence of BCL2 and MYC translocations or TP53 inactivation did not affect sensitivity to ADCx19. ADCx19 was then combined with the BCL2 inhibitor venetoclax in GCB and ABCDLBCL cell lines. The combination of ADCx19 and venetoclax produced synergistic activity in all cell lines.
[0185] Cell line: OCI-LY3 RRID cell accession identifier: CVCL_8800
[0186] [Table 4] Cell line: TMD8 RRID Cell Accession Identifier: CVCL_A442
[0187] [Table 5] Cell line: VAL RRID cell accession identifier: CVCL_1819
[0188] [Table 6] Cell line: WSU-DLCL2 RRID cell accession identifier: CVCL_1902
[0189] [Table 7] conclusion Potent single-agent in vitro anti-lymphoma activity of ADCx19 correlates with its target expression and supports ongoing clinical trials in relapsed / refractory DLBCL. Novel venetoclax combination data demonstrate clinical synergy.
Claims
1. 1. A pharmaceutical composition comprising an anti-CD19 antibody-drug conjugate (ADC) (anti-CD19-ADC) for treating a condition in an individual, said treatment comprising administering to said individual an effective amount of said anti-CD19-ADC and venetoclax, wherein said anti-CD19-ADC is represented by the formula L-(D L ) p, where D L is represented by the following formula I: 【Chemistry 1】 (In the formula, L is an antibody (Ab) that is an antibody that binds to CD19; (a) R L1’ is a linker that binds to the antibody (Ab); (b) R 20 and R 21 both form a double bond between the nitrogen and carbon atoms to which they are attached; (c) m is 0 or 1; and (d) When there is a double bond between C2 and C3, R 2 is methyl, and if there is a single bond between C2 and C3, R 2 Below: 【Chemistry 2】 and when there is a double bond between C2' and C3', R12 is methyl, and when there is a single bond between C2' and C3', R 12 Below: 【Chemistry 3】 (It is) wherein the antibody that binds to CD19 comprises a VH domain having a sequence represented by SEQ ID NO:2 and a VL domain having a sequence represented by SEQ ID NO:8; A pharmaceutical composition, wherein p is 1 to 8.
2. The anti-CD19 ADC has the following formula: 【Chemistry 4】 where Ab is an antibody that binds to CD19 and the DAR is 1-8. The pharmaceutical composition according to claim 1 ,
3. The pharmaceutical composition of claim 1, wherein the anti-CD19 ADC is ADCT-402.
4. The pharmaceutical composition of any one of claims 1 to 3, wherein the treatment comprises administering an anti-CD19 ADC prior to, simultaneously with, or after administration of venetoclax.
5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the treatment further comprises administering a chemotherapeutic agent.
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the individual is a human.
7. The individual has: (i) has or has been determined to have a condition; (ii) has or has been determined to have had a cancer that expresses CD19 or CD19+ tumor-associated non-tumor cells; (iii) has or has been determined to have had a cancer that expresses CD19+ infiltrating cells; (iv) currently undergoing treatment with venetoclax; (v) has been treated with venetoclax; and / or (vi) is refractory to treatment with venetoclax or to a further treatment; The pharmaceutical composition according to any one of claims 1 to 6.
8. The pharmaceutical composition of any one of claims 1 to 7, which has increased efficacy compared to monotherapy with either the anti-CD19-ADC or venetoclax.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the condition is a proliferative disease.
10. The pharmaceutical composition according to any one of claims 1 to 8, wherein the condition is cancer.
11. 11. The pharmaceutical composition of claim 9 or 10, wherein the condition is selected from the group comprising non-Hodgkin's lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic lymphoma (CLL), and marginal zone B-cell lymphoma (MZBL), and leukemias, including hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-v), and acute lymphoblastic leukemia (ALL), including Philadelphia chromosome positive ALL (Ph+ALL) or Philadelphia chromosome negative ALL (Ph-ALL).
12. A pharmaceutical composition comprising an anti-CD19-ADC described in any one of claims 1 to 11 and venetoclax.
13. A pharmaceutical composition according to claim 12 for treating a condition in an individual, said treatment being a treatment according to any one of claims 1 to 11.
Citation Information
Patent Citations
Pyrrolobenzodiazepine-antibody conjugate
JP2015534578A
Pyrrolobenzodiazepine-antibody conjugates
WO2014057117A1
Site-specific antibody-drug conjugates
WO2016166298A1
Combinations of PBD-based antibody drug conjugates with BCL-2 inhibitors
WO2017160954A1
Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
WO2018078123A1
